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ABSTRACT 
Opioids are used widely by clinicians due to their potent analgesic activities and sedative 
properties. However, opioid use or abuse is associated with multiple adverse 
gastrointestinal (GI) symptoms and higher susceptibility to infection caused by pathogens 
with gut origin. Both clinical and laboratory studies implied that opioids showed 
suppressive effects on gut immunity and predisposed critically sick patients to infections 
while the mechanism underlying this defect is still unknown. In the present study we 
investigated how opioids modulate gut epithelial barrier function and immune responses 
of gut associated lymphoid tissue (GALT). We demonstrated significant bacterial 
translocation from gut lumen to mesenteric lymph node (MLN) and liver following 
morphine treatment in wild-type (WT) animals that was significantly attenuated in Toll-
like receptor (TLR2 and 4) knockout mice. We further observed significant disruption of 
tight junction protein organization only in the ileum but not in the colon of morphine 
treated WT animals. Inhibition of myosin light chain kinase (MLCK) blocked the effects 
of both morphine and TLR ligands, suggesting the role of MLCK in tight junction 
modulation by TLR. Additionally we determined the immune responses of GALT to 
polymicrobial sepsis in the presence and absence of opioids by using a murine cecal 
ligation and puncture model. The results showed that opioids accelerated the mortality 
rate of polymicrobial sepsis. During sepsis progression, morphine treatment altered gut 
microbiome and subsequently promoted gram-positive bacterial dissemination, which 
induced excess IL-17A production in a TLR2-dependent manner, resulting in increased 
gut permeability, sustained inflammation and higher mortality. This study improved our 
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understanding of the role of morphine in modulating gut barrier functions and the roles of 
GALT in infection susceptibility, which may provide the potential therapeutic targets for 
novel drug development and lead to more powerful strategy to control or prevent severe 
infectious diseases like sepsis especially in the opioid using and abusing population. 
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CHAPTER 1 
BACKGROUND-LITERATURE REVIEW 
 
1.  OPIOIDS AND ADVERSE GASTROINTESTINAL (GI) 
SYMPTOMS 
 
  
A. Clinical applications of opioids 
 
        Opioids are the drugs of choice for pain management in different clinical conditions 
due to their strong analgesia activities and sedative properties (Devlin and Roberts 2009). 
Opioid-induced analgesia is mediated by activation of opioid receptors, which are widely 
distributed within the central nervous system and throughout the peripheral 
tissues(Devlin and Roberts 2009; Baldo and Pham 2013). 
        To reduce pain and anxiety before and during the surgical procedure, high doses of 
morphine (40mg) or fentanyl (600µg) are used especially for cardiac surgery(Murphy et 
al. 2009). Furthermore, opioids are also a mainstay of therapy for postoperative pain and 
other forms of acute pain in hospitalized patients(Viscusi and Pappagallo 2012). The use 
of patient-controlled analgesia with intravenous opioid like morphine and the use of oral 
opioid like oxycodone are the main strategy for the management of acute postoperative 
pain. For ICU patients, morphine, fentanyl, and hydromorphone are the most frequently 
administered opioids for alleviating pain and facilitating mechanical ventilation(Devlin 
and Roberts 2009).  
        Besides acute pain management, long-term opioids are also the most common means 
of treatment for chronic pain. Today, 15% to 20% of office visits in the United States 
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now include the prescription of an opioid, and 4 million Americans per year are 
prescribed a long-acting opioid(Manchikanti et al. 2012). Most patients eventually take 
opioid dosages equivalent to more than 100 mg of morphine per day for many 
years(States 2014). Opioids including morphine, hydromorphone, oxycodone, 
hydrocodone, codeine, fentanyl, and methadone are generally used to relieve moderate to 
severe pain in cancer patients(Plante and VanItallie 2010). In clinical studies combining 
methadone with another opioid showed improved pain control and less adverse effects. 
Recently various novel formulations of opioids like fentanyl pectin nasal spray and 
transdermal fentanyl matrix patch are showing great promise for the treatment of cancer 
pain(Davis and Walsh 2014; Kress et al. 2008).  
       Unfortunately, the liberalization of laws governing opioids prescriptions for the 
treatment of chronic non-cancer pain by the state medical boards has led to dramatic 
increases in opioid use over the past 20 years. Patients with inflammatory bowl disease, 
rheumatoid arthritis, and pancreatitis usually get opioid prescription for pain management. 
However there is debate about whether opioids are appropriate for the treatment of 
chronic non-cancer pain due to a substantial risk for abuse potential and other adverse 
events(Manchikanti et al. 2012; Dunn et al. 2010). Therefore, more studies are still 
needed for assessment of the benefits and risks of opioid treatment in various clinical 
conditions. 
 
B Opioids and immunosuppression 
 
        Although opioids are widely used for pain management, their adverse effects like 
abuse potential, respiratory suppression and immunosuppression limit their long term use. 
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Over the last century, opioid treatment has been shown to modulate both innate and 
adaptive immunity via direct and indirect pathways(Sabita Roy et al. 2011). Human and 
animal studies have provided a large amount of evidences supporting that opioids can 
modulate the functions of innate immune cells such as neutrophils, macrophages, and 
dendritic cells. Neutrophils are the first line of defense against invading pathogens. Their 
recruitment to infection sites is crucial for effective pathogen clearance. Recent studies 
have demonstrated that chronic morphine treatment results in significant delays and 
reduction in neutrophil recruitment by altering expression of chemokine like keratinocyte 
derived cytokine(Martin et al. 2010). Morphine has been shown to impair bactericidal 
function, leading to inadequate bacterial clearance and thereby increased bacterial 
persistence in the host. The mechanisms underlying this impairment has been shown to 
be due to inhibition of superoxide production(Simpkins et al. 1986; Sharp et al. 1985). 
Like neutrophils, macrophages are another member of innate immune cells responsible 
for bacterial clearance via their phagocytic and bactericidal activities. Morphine 
treatment has been shown to inhibit phagocytosis by inhibiting actin polymerization and 
to attenuate bacterial killing by inhibiting reactive oxygen and NO release(Ninković and 
Roy 2012; Ninkovic 2011). In addition to direct suppressive effects on phagocytic and 
bactericidal functions, morphine treatment also reduces the number of macrophages by 
decreasing the proliferative capacity of macrophage progenitor cells and enhancing 
macrophage apoptosis(Singhal et al. 1998; Sabita Roy et al. 1991). Dendritic cells are one 
of the most important antigen presentation cells responsible for the initiation and control 
of the adaptive immune response. Studies show that morphine inhibits IL-23 production 
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by murine dendritic cells resulting in compromised pulmonary mucosal host defense 
against Streptococcus pneumoniae infection(Ma et al. 2010). 
        Additionally, adaptive immune cells like T cells and B cells are also the targets of 
opioid treatment. In early publications, a decrease in splenic and thymic weight following 
morphine treatment has been observed, implying impaired lymphocyte function(LeVier 
et al. 1994). Morphine has been shown to modulate different aspects of adaptive immune 
response, including antigen presentation, T cell activation and lymphocyte 
migration(Beagles, Wellstein, and Bayer 2004; Wang et al. 2001). Our laboratory has 
shown that morphine inhibits IL-2 transcription in activated T cells in both mouse models 
and human cells(Wang, Barke, and Roy 2007) and that morphine skews T helper lineage 
towards Th2 phenotype (Roy et al. 2001).         
        The global effects of opioids on various innate and adaptive immune cells have been 
well studied over the last century. Recently, pioneering researches on the mucosal 
immune system have revealed distinct features of gut associated lymphoid tissues that are 
unique when compared with other traditional lymphoid organs. However, the effects of 
opioid treatment on these specialized mucosal associated lymphoid tissues have not been 
well characterized yet and remain a significant gap in the knowledge. There is an urgent 
need to fill the gaps in our understanding of the functions of GALT and its roles in 
infection susceptibility, which may lead to more powerful strategy to control or prevent 
severe infectious diseases like AIDS and sepsis in the opioid using and abusing 
population. 
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C Opioid receptor distribution in gut  
 
        Opioids exerts their actions by binding to several subtypes of opioid receptors, 
including (i) µ-receptors, (ii) δ-receptors, (iii) κ-receptors and (iv) non-classical opioid 
receptors(Waldhoer, Bartlett, and Whistler 2004). Originally, opioid receptors were 
thought to express only in central nervous system. However, more and more studies 
provide evidence that opioid receptors are also expressed widely in peripheral tissues 
such as GI tract. Several groups have attempted to characterize opioid receptor 
expression in peripheral tissues using quantitative real-time RT-PCR. Their results 
showed that all µ-,	   δ-,	   and	   κ-receptors have low expression levels in the small 
intestine(Peng, Sarkar, and Chang 2012). Using a similar approach in rats further 
validated the occurrence of µ-,	   δ-,	   and	   κ-receptors in both small and large 
intestine(Wittert, Hope, and Pyle 1996). In gut tissues, opioid receptors are mainly 
expressed in the enteric nervous system, which comprises of the myenteric and 
submucosal plexus. By binding to the opioid receptors in enteric nervous system, various 
endogenous and exogenous opioids are able to modulate GI motility and secretion. 
Besides ENS, opioid receptors expressed on immune cells have been shown to play a role 
in intestinal inflammation(Philippe et al. 2003; McCarthy et al. 2001). More recent 
studies report that the enterocytes isolated from the crypt epithelium of guineapigs have 
both u- and δ- opioid receptors(Lang et al. 1996). Opioid receptor expression in intestinal 
epithelial cells is further supported by Rousseaus’s study, in which they showed that 
opioid receptors in intestinal epithelial cells could be up-regulated by lactobacillus, 
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which may provide novel approaches for the treatment of abdominal pain(Rousseaux et al. 
2007). 
          By activating these opioid receptors in intestinal tissues (Figure 1.1), opioids exert 
their pharmacological and adverse effects in gut, including alleviating abdominal pain, 
modulating GI motility, and suppressing intestinal immune functions. 
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FIGURE 1.1 
 
 
FIGURE 1.1 Opioid receptor distributions in intestines. Opioid receptors are not only 
expressed on neutrons in the myenteric plexus and submucosal plexus, which are 
involved in modulating gut motility and secretion but are also expressed on intestinal 
epithelial cells and immune cells, implying that opioids could impact the gut barrier 
function and immune responses as well. 
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D Adverse GI effects associated with opioid administration 
 
       Adverse GI symptoms like nausea, vomiting, constipation, and bloating are the major 
reasons for discontinuation of opioid use (Figure 1.2), leading to inadequate pain control, 
poor quality of life of patients, and bad clinical outcomes(Miaskowski 2009; Tuteja et al. 
2010; Khansari, Sohrabi, and Zamani 2013).  Nausea and vomiting are one of the 
common side effects associated with opioid analgesics. Multiple mechanisms are 
involved in opioid-induced nausea and vomiting, including direct stimulation of the 
chemoreceptor trigger zone (CTZ) for vomiting, inhibition of gut motility, and 
stimulation of the vestibular apparatus. Opioids are small molecules, which can cross 
blood-brain barrier and stimulate CTZ via the activation of µ and δ receptors. Opioid 
inhibition of gut motility results in gut distension, extended GI emptying time, and 
constipation, which stimulates visceral mechanoreceptors and chemoreceptors to induce 
nausea and vomiting. Other studies suggest that opioids bind to µ	   receptors in the 
vestibular apparatus directly and the stimulation of vestibular apparatus results in nausea 
and vomiting. Today there are several classes of dopamine blockers, anticholinergic 
agents, serotonin antagonists, and prokinetic agents available for treating nausea and 
vomiting. However, since the emetogenic mechanism involved in specific opioids is 
usually complex due to their different specificity for opioid receptors and various 
pharmacokinetic properties, it is important to identify the underlying cause of nausea and 
vomiting from among the multiple causative mechanisms for each patient so that 
effective treatment can be chosen(Porreca and Ossipov 2009). 
       Another adverse symptom associated with opioid treatment is a decrease in GI 
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motility. The normal motor functions of the GI tract are crucial for mixing and propelling 
food particles at rates that allow absorption of nutrients, cleaning the proximal intestine 
of residual food and bacteria, and enabling mass movement. Thus, the bowel dysfunction 
induced by opioid treatment may lead to serious consequences in patients(Ukleja 2010). 
There are multiple mechanisms contributing to opioid-induced decreased GI motility: 
Opioids are able to interact with the opioid receptors on presynaptic nerve terminals in 
the myenteric plexus to initiate signals that increase intestinal resting tone to the point of 
spasm while decreasing propulsive peristaltic waves. Moreover, by binding to µ receptors 
within the ENS, opioids treatment could increase activity of the sympathetic nervous 
system and inhibit vasoactive intestinal peptide release thus affecting gut secretion and 
absorption. The overall decreased gut secretion causes a delay in digestion, increased 
water and sodium reabsorption and formation of dryer and harder stools, which can 
contribute to prolonged transit of the intestinal contents through the GI tract. There are 
two major types of GI motility disorder limiting the clinical application of opioids: 
postoperative ileus and constipation. Prolonged postoperative ileus associated with opioid 
treatment might lead to increased morbidity, increased risk of postoperative nausea and 
vomiting, and delayed return to enteral feeding(Miaskowski 2009). Constipation is 
another type of GI motility disorder occurring with chronic opioid treatment. Although 
laxatives or opioid antagonists can alleviate constipation, their efficacy is still 
insufficient(Tuteja et al. 2010). 
       Despite the observation that opioid receptors are expressed on immune cells within 
the intestinal lamina propria, the effects of opioids on intestinal immune function and 
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inflammation are relatively sparce. Studies using animal models show that both chronic 
morphine and morphine withdrawal can lower host defense to enteric bacteria such as 
Salmonella enterica and Pseudomonas aeruginosa. Opioids can induce bacterial 
translocation into the systemic system resulting in sepsis in mice. Recent study show that 
opioids induced susceptibility to Acinetobacter baumannii or following LPS exposure 
sensitized mice to septic shock and accelerated mortality (LPS)(Hilburger et al. 1997; 
Babrowski et al. 2012; Feng et al. 2006; Ocasio et al. 2004; Breslow, Monroy, Daly, 
Meissler, Adler, et al. 2011). In addition to bacterial translocation, morphine has been 
documented to increase pro-inflammatory cytokine production in rats and accelerate the 
progression of LPS-induced sepsis to septic shock(Greeneltch et al. 2004a; Ocasio et al. 
2004; S Roy, Charboneau, and Barke 1999). In clinical studies, higher circulating 
morphine levels were observed in patients with sepsis, severe sepsis, and septic shock 
compared with healthy controls, implying the role of opioids in the development of 
different infections(Glattard et al. 2010). Overall, both clinical and laboratory studies 
provide evidence that µ-opioid receptors are involved in the development and progression 
of various infectious diseases related to gut pathogens. However, the mechanisms 
underlying compromised gut immune function and increased susceptibility to infections 
after opioid treatment have not been well studied yet. The disrupted GI motility may 
contribute to increased susceptibility to infections with gut origin considering that 
impaired peristalsis results in accumulation of residual food and bacteria in gut lumen. 
Clinical studies imply that the early enteral feeding could enhance immune function and 
decrease the risk of infections in postoperative patients, so delayed enteral feeding 
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because of opioid treatment and subsequent ileus may be responsible for increased risk of 
infection. Besides the indirect effects mediated by GI peristalsis, other direct effects of 
opioids on epithelial cells and immune cells in intestinal lamina propria and gut 
associated lymphoid tissues also play important roles in impaired gut immune function. 
Opioid modulation of GALT will be discussed in the following chapter. 
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FIGURE 1.2 
 
FIGURE 1.2 Adverse GI effects associated with opioid administration. (A) Opioid 
treatment induces nausea and vomiting via CTZ stimulation, vestibular stimulation, and 
GI motility inhibition. (B) Opioid treatment induces GI motility disturbances by 
decreasing propulsive peristaltic waves and inhibiting GI secretion. (C) Opioid treatment 
suppresses gut immunity by influencing gut epithelial cells and immune cells directly or 
by inhibiting GI motility. 
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2.  OVERVIEW OF GUT IMMUNOLOGY 
         To understand the mechanism underlying opioid-induced immunosuppression in 
gut, the functions of intestinal epithelium, immune cells, and the microorganisms resident 
in gut lumen should be considered. 
 
A The structure of gut epithelium 
           The intestinal epithelium is the first line of defense in the gut luminal 
environment. The well-organized intestinal epithelial cells not only provide physical 
barrier preventing potential pathogen or antigen invasion, but also play an important role 
in supporting nutrient and water transport and maintaining the homeostasis of the whole 
organism(Marchiando, Graham, and Turner 2010). The small intestine is where most 
chemical digestion takes place and responsible for absorption of most of the nutrients 
from ingested food. Besides digestion and absorption, the small intestine also plays an 
important role in immune surveillance and defense. To fulfill the multiple functions, the 
stem cells located in the crypt will differentiates into four cell types: i) absorptive 
enterocytes, ii) enteroendocrine cells, iii) goblet cells, and iv) paneth cells 
(Figure1.3)(Barker et al. 2007; Bullen et al. 2006). Absorptive enterocytes and 
enteroendocrine cells in the villus are responsible for digestion and absorption. The 
goblet cells will migrate to the villus from crypt after differentiation and produce large 
amounts of mucins, which is the major component of the mucus layer lining the intestinal 
epithelium(Linden et al. 2008). Paneth cell stays in the base of the crypt after 
differentiation and is the major source of anti-microbial peptides like α-defensins. The α-
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defensins are cysteine-rich cationic peptides with antibiotic activity against a wide range 
of bacteria and other microbes. Studies of transgenic and knockout mice have supported a 
pivotal role of Paneth cell α-defensins in protection from bacterial pathogens(Porter et al. 
2002). Another specialized epithelial cell occurring in small intestine is called the M cell 
(or microfold cell). M cells are found in the follicle-associated epithelium overlaying the 
peyer’s patches. Unlike other intestinal epithelial cells, there is no mucus covering M 
cells, thus it plays a unique role in antigen presentation(Mabbott et al. 2013). In addition 
to epithelial cells differentiated from the crypt epithelial stem cells, some immune cells 
are also interspersed between epithelial cells. These include the dendritic cells and 
intraepithelial lymphocytes. In the intestines, dendritic cells can penetrate the epithelium 
to actively sample the antigens from the mucus layer(Rescigno and Sabatino 2009). The 
intraepithelial lymphocytes are mainly involved in insuring the integrity of gut epithelium 
and maintaining the balance between normal immune responses and excessive 
inflammation(Cheroutre 2005). 
         The major function of the colon is reabsorption of water and any remaining soluble 
nutrients from the food. There is no villus in the colon because it doesn’t need as much 
surface area as the small intestine. Therefore, the epithelial stem cells are usually located 
in the lower parts of gut crypts and the differentiated cells migrate to the higher position 
and populate the colonic epithelial surface(Barker et al. 2007). To avoid paracellular leak 
of bacteria from gut lumen, the intercellular junctions known as tight junctions join 
adjacent cells together. These will be discussed in the following chapter. 
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FIGURE 1.3 
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FIGURE 1.3 Structure of gut epithelium. In the small intestine, the epithelial stem 
cells located in the crypt will differentiate into four cell types: the absorptive enterocytes, 
enteroendocrine cells, goblet cells, and paneth cells. In the colon, the epithelial stem cells 
are usually located in the lower parts of gut crypts and the differentiated cells migrate to 
the higher position and populate the colonic epithelial surface.   
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B Immune cells in lamina propria, GALT, and MLN  
       Different types of immune cells are distributed in lamina propria, mesenteric lymph 
node, or gut associated lymphoid tissues (GALT) like Peyer's patches (PPs), and isolated 
lymphoid follicles. The major immune cell population within gut tissues includes 
macrophages, dendritic cells, mucosal mast cells, neutrophilic granulocyte, eosinophilic 
granulocyte, T lymphocytes, and plasma cells. These cells can modulate the intestinal 
microenvironment by secreting antibodies, cytokines, or chemokines as well as 
interaction with ENS.  
        In both humans and rodents, Peyer’s patches are organized lymphoid nodules 
usually found in the ileum and less frequently in the jejunum. PPs are usually covered by 
follicle associated epithelium which contains special M cell. M cell can sample antigen 
directly from the gut lumen and deliver it to antigen-presenting cells like dendritic cells. 
T cells, B-cells and memory cells in PPs are stimulated upon encountering antigen. These 
cells then pass to the mesenteric lymph nodes to amplify the immune response. PPs are 
not present in the colon. Isolated lymphoid follicles provide immune surveillance and 
protection against the potential pathogen instead of PPs (Lycke and Bemark 2012; Suzuki 
et al. 2010; Koboziev, Karlsson, and Grisham 2010).  
             In the lamina propria, antigen presenting cells including dendritic cells, 
macrophages, and neutrophils. These cells recognize the antigens from the gut lumen and 
present them to adaptive lymphocytes (T cells and B cells) to initiate the subsequent 
responses. Various cytokines and chemokines produced by these APCs are also involved 
in the regulation of intestinal inflammation (Farache et al. 2013). The major populations 
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of T cells in the lamina propria are the CD4 T Cells, predominated by Th1 and Th17 
population. Th1 cells produce IFN-γ, a cytokine important for the control of virus 
infection and responsible for the pathogenesis of inflammatory bowel disease. Th17 cells 
produce Th17 cytokines including IL-17A, IL-17F, and IL-22(Shale, Schiering, and 
Powrie 2013). Th17 cytokines play an important role in host defense against extracellular 
pathogens, which will be discussed in the following part. IgA+ plasma cells are the 
dominant population in the lamina propria. The secretory IgA produced by plasma cells 
can neutralize toxins and mediate ingestion of pathogen via opsonization(Suzuki et al. 
2010). 
        The mesenteric lymph node (MLN) drains PPs and isolated lymphoid follicles via 
afferent lymphatics. By receiving the signals presented by dendritic cells, MLN amplify 
the immune responses. In this way, MLN plays a key role in tolerance induction to food 
proteins and in host defense against the pathogens from the gut lumen(Mason et al. 
2008). 
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FIGURE 1.4 Composition of gut immune system. The major immune cell population 
within gut tissues includes macrophages, dendritic cells, neutrophilic granulocyte, T 
lymphocytes, and B-lymphocytes. The Peyer’s patches in the small intestine and the 
isolated lymphoid follicle in the colon are composed of dendritic cells, B cells and T 
cells, which are crucial for antigen presentation from gut lumen. 
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C Gut microbiota in gut immunity 
        Gut commensal microbiota is an important compartment of gut immune system 
usually neglected previously. They play an important role in maintaining the intestinal 
homeostasis (Figure 1.5). Firstly, they are able to metabolize the toxic xenobiotic agents 
into harmless metabolite. They are also able to exclude the potential pathogens in the gut 
lumen(Sekirov et al. 2010). Secondly, they are involved in formation of mucus layer 
outside the epithelium. Previous studies have shown that microbial flora influences the 
number of goblet cell, their mucin production, and the glycosylation of mucins(Gaskins 
2001). Moreover, they are also essential for the development of lymphoid tissues like PPs 
and modulate T cell and B cell responses(Lee and Mazmanian 2010). For example, most 
commensal bacteria have no direct contact with intestinal epithelial cells except for the 
segmented filamentous bacteria (SFB), which are able to adhere to epithelial cells 
especially to those in PPs. Interestingly, recent studies show that the mice without SFB 
have significantly less IL-17 production in their intestines, implying the important role of 
SFB in Th17 differentiation(Ivanov et al. 2009). Not surprisingly, lack of gut commensal 
microbiota will result in abnormalities such as increased susceptibility to infectious 
diseases. For example, germ-free mice showed increased susceptibility to Salmonella due 
to impaired IgA production and diminished T cell response(Hapfelmeier et al. 2010). 
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FIGURE 1.5 
 
FIGURE 1.5 Gut microbiota in gut immunity. (A) Gut microbiota is able to 
metabolize the toxic xenobiotic agents into harmless metabolite. (B) Microbial flora 
influences mucin production by goblet cells. (C) Microbial flora influence lymphocyte 
responses. 
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3.  TIGHT JUNCTIONS IN GUT EPITHELIUM 
 
A The structure and function of TJ in gut epithelium 
        As discussed previously, tight junction proteins are located between the gut 
epithelial cells and their functions are to allow the transport of small solutes, water, and 
some macromolecules through the paracellular pathway selectively and exclude the 
potentially harmful molecules. Tight junction proteins in the intestinal epithelium 
includes transmembrane proteins such as the occludin and the claudin family members, 
which seal the paracellular pathway between the epithelial cells. In addition to 
transmembrane molecules, the paracellular proteins such as zona occludens-1 (ZO-1) and 
zona occludens-2 (ZO-2), play an important role in supporting the organization of TJ 
proteins(Peterson and Artis 2014). The permeability of tight junction is dynamic and 
determined by the isoforms, quantity, and organizations of these proteins. Disruption of 
gut tight junction protein results in barrier defects and is associated with various intestinal 
diseases. For example, the genetic polymorphisms of the tight junction protein have been 
linked to celiac disease, ulcerative colitis, and Crohn’s disease(Schulzke et al. 2009). 
 
B Toll like receptor and TJ in gut epithelium 
        The Toll-like receptor (TLR) family plays an important role in innate immunity and 
TLR signaling has to be regulated tightly in the intestines to maintain the balance 
between normal and over-exuberant activation due to the presence of large amount of 
commensal bacteria in the lumen of the gastrointestinal tract(Abreu 2010). Among all 
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TLRs in the gut, TLR2 and TLR4 play a dominant role in physiological and pathological 
processes, and are both involved in intestinal permeability regulation. TLR2 and TLR4 
have been shown to regulate the gate-keeping functions of the intestinal follicle-
associated epithelium(Chabot et al. 2006). In contrast, activation of TLR4 by LPS 
increases the permeability of intestinal cell monolayer by disrupting the complex 
consisting of tight junction proteins, myosin, and F-actins. This process is mediated by 
myosin light chain kinase (MLCK) (Figure 1.6)(Forsythe et al. 2002). Besides the direct 
effects on tight junction organization, TLR signaling is also involved in barrier 
modulation indirectly since TLR activation leads to production of various pro-
inflammatory cytokines. Studies from different groups reported that interferon-γ, tumor 
necrosis factor-α, and interleukin-1β could increase the intestinal cell permeability by 
changing the expression and localization of tight junction proteins(Tazuke et al. 2003; 
Utech et al. 2005; Bruewer et al. 2003; Desai et al. 2002). IL-17 is pro-inflammatory 
cytokine associated with different autoimmune diseases especially inflammatory bowel 
disease like Crohn’s disease and colitis(Gu, Wu, and Li 2013). In contrast, one study 
correlated the compromised gastrointestinal integrity in pigtail macaques with high levels 
of IL-17 production(Klatt et al. 2010). The exact effects of IL-17 on intestinal tight 
junction are still elusive. Interestingly, other researches focusing on tight junctions in 
endothelial cells that make up the blood brain barrier provide the potential mechanism by 
which IL-17 modulates tight junction proteins and the barrier functions. In these studies, 
IL-17 treatment resulted in reduced expression levels of tight junction protein and tight 
junction disorganization in MLCK-dependent manner(Huppert et al. 2010; Kebir et al. 
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2007). 
C Opioids and TJ functions 
        The effects of opioid treatment on intestinal barrier function still remain to be 
determined while researches investigating tight junctions in blood brain barrier (BBB) 
imply the role of opioids in tight junction protein modulation and function. For example, 
morphine treatment has been shown to induce release of pro-inflammatory cytokines 
TNF- α, which significantly decreased both ZO-1 and occludin gene expression in brain 
microvascular endothelial cells, resulting in impaired barrier function of BBB(Mahajan et 
al. 2008). 
         There is abundant evidence demonstrating that intracellular cross talk between 
MOR signaling and TLR signaling in various kinds of cells results in alteration of 
immune responses and progress of inflammation. For example, our lab has recently 
shown that chronic morphine treatment can synergistically increase and activate TLRs in 
the presence of HIV-1 protein TAT and S. pneumonia in microglial cells, which induced 
a significant increase in pro-inflammatory cytokines (IL-6, TNF-α) levels. Therefore the 
crosstalk between MOR signaling and TLR signaling might provide the potential 
mechanism by which opioid treatment modulate intestinal tight junction protein function 
(Dutta et al. 2012). 
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FIGURE 1.6 
 
FIGURE 1.6  TLR activation modulates TJ organization in a MLCK-dependent 
pathway. Activation of TLRs by TLR ligands increases the permeability of intestinal 
epithelial cells by disrupting the complex consisting of tight junction proteins, myosin, 
and F-actins in a MLCK-dependent manner. 
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4.  IL-17 CYTOKINES AND GUT IMMUNITY 
 
A IL-17 cytokines and their functions 
       The IL-17 family consists of six members, which include IL-17A-F. By binding to 
IL-17 receptors in various tissues, IL-17 cytokines participate in acute and chronic 
inflammatory responses, playing a crucial role in host defense against microbial 
infections and acting as pro-inflammatory cytokines involved in pathogenesis of 
autoimmune diseases like IBD. The IL-17 receptor family now consists of five members, 
which are IL-17RA, RB, RC, RD and RE. IL-17RA is a common receptor forming 
heterodimers with IL-17RB, IL-17RC, and IL-17RE and all of these receptors needs 
AKT as the adapter molecule to initiate the downstream signaling pathways (Figure 
1.7)(Gu, Wu, and Li 2013). 
       Among all IL-17 cytokines, IL-17A and IL17F are the most widely investigated in 
the recent studies. All IL-17A and IL-17F homodimers and IL-17AF heterodimers bind 
to heterodimeric receptor complex composed of IL-17RA and IL-17RC. IL-17A shares 
56% sequence homology with IL-17F and has 100–1000 times higher affinity for IL-
17RA than does IL-17F whereas the binding affinities for IL-17RC is comparable 
between the two cytokines. IL-17A is able to synergize with other molecules like TNF-α 
to enhance pro- inflammatory responses via enhancing the chemokine expression through 
stabilizing these mRNAs(Chang and Dong 2011; Gu, Wu, and Li 2013). Depletion of IL-
17RA or IL-17A in murine models resulting in increased host susceptibility to a variety 
of pathogen infection such as Salmonella enterica, Streptococcus pneumoniae, 
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Staphylococcus aureus, Helicobacter pylori, and Citrobacter rondentium etc., thus 
demonstrating the essential role of IL-17 in host defense(Chang and Dong 2011; Gu, Wu, 
and Li 2013; Rubino, Geddes, and Girardin 2012). However, IL-17A is also identified as 
the major driver for several inflammatory and autoimmune diseases like multiple 
sclerosis (MS), psoriasis, asthma, Crohn’s disease and rheumatoid arthritis(Akdis et al. 
2012; Chang and Dong 2011). The controversial roles of IL-17 in the gut have attracted 
more attention recently.  On one hand, IL-17A, IL-17F, and Th17 cells are abundantly 
up-regulated in the intestinal mucosa of Crohn’s disease and ulcerative colitis patients 
and both IL-17R-deficiency and IL17F-difficiency protected mice from acute 
trinitrobenzenesulfonic acid (TNBS) - or dextran sodium sulfate (DSS)-induced colitis. 
On the other hand, several studies showed that the protective role of IL-17A in T-cell 
mediated colitis by inhibiting Th1 polarization for IFN-γ dependent inflammation(Akdis 
et al. 2012; Sanchez-Muñoz 2008; Strober and Fuss 2011; O’Connor et al. 2009). 
Therefore, more investigations are needed to understand the exact functions of IL-17A 
and F in the intestinal tissues. The function of IL-17C is very similar to IL-17A. By 
binding to the IL-17RA-RE complex, it mediates host defense responses and contributes 
to the pathogenesis of autoimmune diseases(Gu, Wu, and Li 2013). 
          IL-17E, known as IL-25 as well, exerts very different functions from IL-17A. Its 
signaling through the IL-17RA-RB receptor complex induces Th2 responses by 
activating MAPK NF-κB pathways. Due to high levels of IL-17-RB in lung, IL-17E can 
induce lung inflammation by promoting the differentiation of naïve T cells to effector 
Th2 cells. In human asthmatic tissue, both IL-17E and IL-17RB expression were shown 
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to be elevated compared to healthy controls, implying that IL-17E is involved in allergic 
airway inflammation. The targets and activities of IL-17B and IL-17D still need future 
investigation(O’Connor et al. 2009; Swaidani et al. 2009; Swaidani et al. 2011). 
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FIGURE 1.7 
 
FIGURE 1.7 IL-17 cytokine family and their functions. IL-17A and IL-17F bind to 
complexes of IL-17RA and IL-17RC to initiate the signaling pathway involved in host 
defense and tissue inflammation. IL-17C binds to complexes of IL-17RA and IL-17RE 
and shows the similar activity to IL-17A.  IL-17E binds to complexes of IL-17RA and 
IL-17RB to initiate Th2 and allergic responses. 
   29 
 
B IL-17 responses in immunity and inflammation 
        In response to bacteria stimulation, different types of intestinal immune cells 
including CD4+ Th17 cells, CD8+ T cells, γδT cells, natural killer (NK) cells, innate 
lymphoid cells, and neutrophils, are able to produce IL-17 to mediate the defense 
mechanism and induce the inflammatory progress(Rubino, Geddes, and Girardin 2012). 
Th17 cells were the first cell population reported to produce IL-17A and IL-22. However, 
the differentiation pathways that lead to Th17 cells are not clearly defined. In early 
studies, it was postulated that Th17 cells were derived form naïve precursors in the 
presence of IL-6 and TGF-β and that IL-23 acts downstream of IL-6 and TGF-β to 
sustain the Th17 phenotype. However, subsequent studies show that IL-6, IL-1β, and IL-
23 can also differentiate naïve T cells into Th17 cells in the absence of TGF-β. 
Interestingly, the effector cytokines produced by Th17 cells from these two 
differentiating pathways are different. The cells derived via the TGF-β dependent 
pathway are identified as more regulated classical Th17 cells characterized by the 
production of more IL-21, IL-9, and IL-10, which may play a more protective role in 
maintenance of barrier integrity in intestinal mucosal sites. Whereas the cells derived 
through TGF-β independent pathway produce high levels of IL-22, GM-CSF, and IFN-γ, 
which may play a more prominent role in pathogenic inflammation in infectious or 
autoimmune diseases (Figure 1.8)(Akdis et al. 2012). 
         In addition to CD4+ Th17 cells, many other innate immune cells also produce IL-17 
as well. For example, neutrophils have been shown to induce the expression of IL-17A 
and IL-17RC following stimulation with IL-6 and IL-23, which probably contribute to 
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the etiology of microbial and inflammatory diseases(Taylor et al. 2014). Furthermore, 
pattern recognition receptors (PRRs) such as TLR2 also mediate rapid IL-17 production 
in response to bacteria encounter in γδ T cells. More recently, it was discovered that there 
exists a group of innate lymphoid cells (ILCs) belonging to the lymphoid lineage. So far, 
three groups of ILCs has been characterized, among which the group three ILCs are the 
important sources of IL-17 and IL-22 during early phases of infection(Rubino, Geddes, 
and Girardin 2012). 
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FIGURE 1.8 
 
FIGURE 1.8 Th17 cells derived via two different pathways. The Th17 cells derived 
via the TGF-β dependent pathway are identified as more regulated classical Th17 cells 
which may play a more protective role in maintenance of barrier integrity in intestinal 
mucosal sites. Whereas Th17 cells derived through the TGF-β independent pathway 
produce high levels of pro-inflammatory cytokine, which may play a more prominent 
role in pathogenic inflammation in infectious or autoimmune diseases. 
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C Opioid treatment and IL-17 responses 
            Since IL-17 is a cytokine discovered pretty recently, not many studies have been 
performed to understand the influence of opioid treatment on IL-17 responses and the 
results of these studies are confusing. Some studies imply the inhibitory effects of opioids 
on IL-17 production. For example, in an intranasal S Pneumonia infection model, our lab 
reported that morphine administration reduced dendritic cell IL-23 expression and 
impaired IL-17A production by γδ T cell, resulting in increased susceptibility to 
Pneumonia(Ma et al. 2010). Another group reported the similar results: morphine 
treatment suppressed the expressions of IL-17A and other chemokines, which are crucial 
for neutrophil recruitment. The impaired neutrophil recruitment sensitized mice to 
Acintobacter infection and led to increased mortality of mice during infection(Breslow, 
Monroy, Daly, Meissler, Gaughan, et al. 2011). Whereas other group showed that 
circulating Th17 numbers were not significantly altered but the production of IL-17A was 
significantly increased by chronic morphine treatment(Cornwell et al. 2013). All these 
results suggest that multiple mechanisms are involved in IL-17 regulation and that more 
investigations are required to understand the role of opioids in IL-17 responses. 
. 
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CHAPTER 2 
OPIOID TREATMENT MODULATES GUT EPITHELIAL 
BARRIER FUNCTION 
 
INTRODUCTION 
        Morphine is the most widely used analgesic worldwide for the management of pain. 
Morphine use is especially prevalent in patients undergoing invasive procedures that are 
associated with long operative times and extended hospitalization(Regan L, Chapman 
AR, Celnik A, Lumsden L, Al-Soufi R 2013; Ripamonti and Bruera 1991). Clinically, 
morphine use has been shown to be an independent risk factor for infection and infection-
related morbidity in burn patients(Alexander et al. 2005; Sabita Roy et al. 2011). 
Furthermore, clinical studies have reported that patients with sepsis, severe sepsis, and 
septic shock had significant higher circulating morphine levels than patients with 
systemic inflammatory response syndrome and healthy controls(Glattard et al. 2010), 
while the opioid antagonist naltrexone has been shown to block acute endotoxic shock by 
inhibiting tumor necrosis factor-α production(Greeneltch et al. 2004a). Studies using 
animal models show that both chronic morphine and morphine withdrawal can lower host 
defense to enteric bacteria such as Salmonella enterica and Pseudomonas aeruginosa, 
induce spontaneous sepsis in mice, and sensitize mice to mortality induced by 
Acinetobacter baumannii infection or lipopolysaccharide (LPS) (Greeneltch et al. 2004a; 
Ocasio et al. 2004; S Roy, Charboneau, and Barke 1999). In addition to bacterial 
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translocation, morphine has been documented to sustain high serum IL-6 levels and 
accelerate the progression of LPS-induced sepsis to septic shock(Banerjee et al. 2013; 
Ocasio et al. 2004). Overall, both clinical and laboratory studies provide evidence that µ-
opioid receptors are involved in the development and progression of various infectious 
diseases related to gut pathogens. However, the mechanisms underlying compromised gut 
immune function and increased susceptibility to infections after morphine treatment have 
not been well characterized. Therefore, the objective of the present study was to 
understand the correlation between morphine treatment and compromised gut barrier 
function, in order to support the development of novel strategies to treat or prevent gut 
bacterial infection in opioid-using or -abusing populations. 
       Epithelium is one of the most important components of intestinal mucosal immunity, 
which is required for prevention of potential pathogen invasion. The intestinal 
epithelium, as the first line of defense in the gut luminal environment, is not only a 
simple physical barrier but also plays an essential role in supporting nutrient and water 
transport and maintaining the homeostasis of the whole organism. Not surprisingly, 
compromised barrier function allows the intestinal microbiota to translocate through the 
epithelium, leading to increased susceptibility to infection by gut pathogens, and faster 
progression of infectious disease(Turner 2009). Gut epithelial cells play an important role 
in recognizing and preventing potential pathogen or antigen invasion. To accomplish 
these complicated functions, well-organized transmembrane and paracellular tight 
junction proteins are expressed in these polarized cells. Tight junction proteins in 
intestinal epithelium include transmembrane proteins such as occludin and claudin family 
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members, which seal the paracellular pathway between the epithelial cells, as well as 
paracellular proteins such as zona occludens-1 (ZO-1) and zona occludens-2 (ZO-2), 
acting as scaffolding molecules. Disruption of gut tight junction barrier function has 
severe consequences including bacterial translocation from the gut leading to immune 
activation and inflammation(Schulzke et al. 2009). 
       Toll-like receptor (TLR) signaling is one of the most important components of innate 
immunity and has to be regulated tightly in gut epithelium to maintain the balance 
between normal and over-exuberant activation due to the presence of large amount of 
commensal bacteria in the lumen of the gastrointestinal tract(Abreu 2010). Among all 
TLRs in the gut, TLR2 and TLR4 play important roles in physiological and pathological 
processes, and are both involved in intestinal permeability regulation. TLR2 and TLR4 
have been shown to regulate the gate-keeping functions of the intestinal follicle-
associated epithelium. Paradoxically, activation of TLR4 by LPS increases intestinal 
monolayer permeability in a myosin light chain kinase (MLCK)-dependent manner 
(Moriez et al. 2005). Meanwhile, there is evidence showing intracellular cross talk 
between MOR signaling and TLR signaling in various kinds of cells(Sabita Roy et al. 
2011). For example, morphine significantly inhibits tumor necrosis factor-α (TNF- α), but 
not interleukin-6 (IL-6) production, in a MOR-independent manner in polyglycan-
stimulated peripheral blood mononuclear cells(Bonnet et al. 2008). However, the 
intracellular mechanism underlying how morphine compromises epithelial barrier 
function via modulating TLRs is still not defined. In the present study, we hypothesize 
that morphine disrupts the barrier function of gut epithelium by increasing the sensitivity 
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of gut epithelial cells to TLR activation, resulting in bacterial translocation from the gut 
lumen. We investigated the effects of morphine on gut barrier function in wild type 
(WT), TLR2 knockout, TLR4 knockout, and TLR2/4 double knockout mice. The direct 
effects of morphine on gut epithelial cells were further studied with rodent small 
intestinal and colonic epithelial cell lines, IEC-6 and CMT-93, respectively. Our results 
from in vivo and in vitro studies indicate that morphine treatment compromises gut 
barrier function in a TLR-dependent manner. 
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METHODS 
Experimental animals 
       Pathogen-free B6129PF2, C57BL/6J, B6.129Tlr2tm1Kir/J (TLR2 knockout) and 
C57BL/10ScNJTlr4lps-del (TLR4 knockout) mice were obtained from the Jackson 
Laboratory (Bar Harbor, ME). We crossed TLR2 knockout withTLR4 knockout mice to 
generate TLR2/4 double knockout mice. MOR knockout (MORKO) mice 
(C57BL/6129/Ola genetic background) were generated by Loh and his colleagues(S Roy, 
Barke, and Loh 1998). Briefly, a XhoI/XbaIfragment, which spans exons 2 and 3, was 
replaced with a Neor cassette, followed by the ligation of a thymidine kinase expression 
cassette to the 3′ end of this segment. All animals were housed in a specific-pathogen-
free facility under barrier conditions. All animal experiments were done in accordance 
with the Institutional Animal Care and Use Committee's guidelines at the University of 
Minnesota. The protocol was approved by Institutional Animal Care and Use Committee 
(IACUC) at the University of Minnesota (protocol# 0909A72719). All surgeries were 
performed under isoflurane anesthesia, and all efforts were made to minimize suffering. 
 
Animal treatment 
      Mice received morphine and pellet implantation method as described. Using this 
method, plasma levels of morphine are in the 0.6–2.0-microg/ml range (range seen in 
opioid abusers and patients on opioids for moderate to severe pain). Furthermore, this 
model is commonly used in the study of opiate dependence and addiction(Bryant et al. 
1988). Briefly, placebo or 75 mg morphine pellets (National Institutes of Health 
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[NIH]/National Institute on Drug Abuse [NIDA], Bethesda, MD) were inserted in a small 
pocket created by a small skin incision on the animal's dorsal side; incisions were closed 
using surgical wound clips (Stoelting, 9 mm Stainless Steel, Wooddale, IL). Animals 
were injected with MLCK inhibitor ML-7 (2 mg/kg) overnight before LPS or 
Lipoteichoic acid (LTA) treatment. At this dose, ML-7 successfully inhibited activity of 
myosin light chain kinase and protected the barrier function of endothelial cells in 
mice(Huppert et al. 2010). 
 
Intestinal permeability 
       All animals were gavaged with ampicillin-resistant E. coli (2×107 CFU suspended 
in 400 µl of sterile saline) or FITC-dextran (600 mg/kg body weight in 20 mg/ml 
concentration) utilizing a 4-cm long, curved needle with a plastic ball at the tip. After 
sacrifice, MLN and liver were collected and cultured on LB plates containing 100 µg/ml 
of ampicillin to measure bacterial translocation. Whole blood FITC-dextran concentration 
was determined by fluorometry based on a standard curve. 
 
Immunofluorescence 
       Sections of small intestinal and colonic tissue from all mice sacrificed for tight 
junction staining were frozen in TFM™ tissue freezing medium (TBS, Durham, NC). At 
least five sections from each of three animals for each condition were analyzed by 
immunofluorescence microscopy. Representative images are shown. For 
immunostaining, 5 µm frozen sections were fixed with 1% paraformaldehyde in PBS for 
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10 min at room temperature. After washing in PBS and blocking of nonspecific binding 
sites with 5% bovine serum albumin (BSA), tissues were incubated with polyclonal 
rabbit anti-occludin or rabbit anti-ZO-1 (both used at 5 µg/ml, Invitrogen) in PBS with 
5% bovine serum albumin (BSA) for 120 min at room temperature. After washing, 
sections were incubated with rhodamine phalloidin (Invitrogen) and DyLightTM 488-
conjugated AffiniPure Donkey anti-rabbit IgG (0.075 mg/ml, Jackson Lab, WestGrove, 
PA) for 60 min. Sections were then washed and mounted under coverslips using ProLong 
Gold antifade reagent with DAPI (Invitrogen). Sections were imaged using a confocal 
microscope (Nikon). Image J RG2B co-localization software was used to quantify the 
intensity of yellow fluorescence (indicating co-localization of green and red) and 
normalized to blue fluorescence (DAPI). 
 
Western blots 
       Cells were lysed with radioimmunoprecipitation assay (RIPA) buffer (Sigma). 
Lysates (80 µg protein per lane) were separated by SDS-PAGE, and proteins were 
electrotransferred from gel onto nitrocellulose membrane. Membranes were blocked in 
Tris-buffered saline, 0.1% Tween 20, 5% BLOT-QuickBlockerTM (G-Biosciences, St 
Louis, MO), and incubated with primary and secondary IRDye® anti-IgG Abs (LI-COR 
Biosciences). Protein bands were visualized using Odyssey infrared imaging system (LI-
COR Biosciences). 
 
Realtime PCR 
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      Total cellular RNA was extracted using TRIzol (Invitrogen), and cDNA was 
synthesized with the M-MLV Reverse Transcription Kit (Promega). Primers for TLR2, 
TLR4, and 18S ribosomal RNA were purchased from IDT. Quantitative real-time 
polymerase chain reaction (PCR) was performed on an Applied Biosystems 7500 
Realtime PCR Detection system. All samples were run in triplicate, and relative mRNA 
expression levels were determined after normalizing all values to 18S RNA. Primer 
sequence: 18S: 5-GTAACCCGTTGAACCCCATT-3; 5-
CCATCCAATCGGTAGTAGCG-3; TLR2: 5-CGCCTAAGAGCAGGATCAAC-3; 5-
GGAGACTCTGGAAGCAGGTG-3; TLR4: 5-CCAGAGCCGTTGGTGTATCT-3; 5-
TCAAGGCTTTTCCATCCAAC-3. 
 
Epithelial cell isolation 
       Epithelial cells were isolated as described previously(Roulis et al. 2011). Small 
intestine was excised from mice, flushed with HBSS/2% FBS, opened longitudinally, and 
cut into 0.5-cm pieces. The tissue was further washed and incubated in HBSS/2% FBS, 
0.5 mM EDTA, and 1 mM DTT, at 37°C in shaking water bath for 45 min. The cell 
suspension released upon vigorous shaking was layered on a discontinuous 25%/40% 
Percoll gradient (Sigma) and centrifuged at 600×g for 10 min. Intestinal epithelial cells 
(IEC) were collected from the interphase and incubated with anti-cytokeratin antibody 
(BD Pharmingen), anti-TLR2 and anti-TLR4 antibodies (eBiosciences). 
 
Cell culture and treatment 
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       IEC-6 and CMT-93 cell lines were purchased from American Type Culture 
Collection (Manassas, VA) and cultured as recommended by the supplier. IEC-6 and 
CMT-93 cells are rodent small intestinal and colonic epithelial cell lines. Cells were 
pretreated with MLCK inhibitor ML-7 before LPS (1 µg/ml, Sigma) or LTA (5 µg/ml, 
Sigma) stimulation. Inactivation of MLCK by ML-7 has been shown to protect barrier 
function in various endothelial and epithelial cell lines(Huppert et al. 2010). 
 
Measurement of trans-epithelial resistance 
     ECIS 1600R (Applied BioPhysics, Troy, NY) was used to measure trans-epithelial 
resistance (TER) of epithelial monolayers as described previously [29]. Epithelial cells 
were seeded in the wells of the electrode array and grown to confluence as indicated 
below. Then medium was exchanged, and baseline TER was measured for 60 min to 
equilibrate monolayers. Afterward, 400 µl of medium containing ML-7 (10 µM), LPS (1 
µg/ml), or LTA ((5 µg/ml) was applied to the wells. 
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RESULTS 
Chronic Morphine compromises the barrier function of gut epithelium and promotes 
bacterial translocation 
       To determine whether chronic morphine treatment modulates bacterial 
dissemination, we determined spontaneous gut bacterial translocation following 
morphine treatment. B6129PF2 wild type mice were implanted with 75 mg morphine or 
placebo pellet subcutaneously. Mesenteric lymph node (MLN) (n = 9) and liver (n = 10) 
suspensions were collected after 24 hours, cultured on blood agar plates (BD 
Biosciences) overnight and the colony forming units (CFUs) were quantified. Placebo-
implanted mice showed no colonies growing on the plates, indicating no bacterial 
translocation. Conversely, mice receiving morphine revealed an increased number of 
CFUs, indicating bacterial dissemination to MLN and liver following 24 hours of 
morphine treatment (Figure 2.1A). At 48 hours, morphine-induced bacterial translocation 
into liver and MLN persisted (Figure 2.1E). To determine the role of μ-opioid receptors 
(MOR) in morphine modulation of bacterial translocation, we implanted MOR knockout 
(MORKO) mice with morphine pellets, as described above. Morphine-induced bacterial 
translocation was completely abolished in MORKO mice (Figure 2.1B), suggesting that 
MOR mediated morphine's effects on bacterial translocation. To further confirm that the 
disseminated bacteria were from the gut lumen rather than opportunistic infections, we 
gavaged WT mice with ampicillin-resistant E.coli and quantified bacterial translocation 
with Lysogeny broth (LB) plates containing ampicillin. Morphine-treated mice showed 
ampicillin-resistant E.coli dissemination into MLN and liver (Figure 2.1C), indicating 
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that morphine treatment promotes bacterial translocation of commensal bacteria from the 
gut lumen. In addition, morphine treatment promoted fluorescein isothiocyanate (FITC)-
conjugated dextran translocation from gut lumen to blood (Figure2.1D), suggesting that 
morphine increased the permeability of the gut epithelium. Serotyping of the 
disseminated bacteria (Veterinary Diagnostic Laboratory, University of Minnesota) 
revealed a prevalence of Staphylococcus, Enterococcus, and Bacillus sp., which are 
commensal bacteria in the gut lumen. 
 
Chronic morphine induces inflammation and disrupts organization of tight junction 
proteins between epithelial cells in small intestine 
       To investigate the effects of morphine on the morphology of the intestinal 
epithelium, small intestine and colon were excised and fixed in a formalin solution for 
hematoxylin and eosin (H&E) staining. Histological analysis showed injured epithelium 
and increased inflammatory infiltrates in small intestinal villi of morphine-treated mice 
(Figure 2.2). In contrast, no morphological change was observed in the colon of 
morphine-treated mice, suggesting a differential effect by morphine on small intestinal 
and colonic epithelium. Our findings of morphine-induced microbial translocation and 
barrier compromise in the small intestine of mice prompted us to study the tight-junction 
organization of the intestinal epithelium. Wild-type mice were implanted with placebo or 
75 mg morphine pellet for 24 hours. Then parts of the small intestine were excised, 
frozen and 5 µm sections were cut. The sections were stained for occludin and zona 
occludens 1 (ZO-1), two proteins integral to the formation of epithelial tight-junction. In 
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placebo treated mice, the trans-membrane protein occludin localized to the apical side of 
epithelium with a continuous and intact organization (Figure 2.3A). Images showed that 
occludin co-localized with the well-organized F-actin on the membrane of epithelial cells 
of placebo-treated mice (Figure 2.3A). In contrast, morphine treated mice showed 
disrupted localization of occludin, suggesting impaired recruitment of the protein to the 
membrane (Figure 2.3B). Similar to occludin, the paracellular tight junction protein ZO-1 
also localized with F-actin on the apical side of the membrane in placebo-treated mice, 
and its organization was seen to be disrupted following 24 hours of morphine treatment 
(Figure 2.3C). Morphine treatment did not change the expression levels of occludin or 
ZO-1 (Figure 2.4), suggesting that morphine modulated the distribution of tight junction 
proteins, resulting in increased intestinal permeability. Quantification of yellow 
fluorescence (indicating the co-localization of red and green) also showed significant 
reduction in the co-localization of tight junction and F-actin in morphine-treated mice 
(Figure 2.3B and D). In MORKO mice, consistent with our bacterial translocation data, 
morphine did not have any effect on occludin and ZO-1 organization in the small 
intestine, indicating that morphine's effect on intestinal tight junction were mediated by 
MOR (Figure 2.3E). Interestingly, morphine did not have an effect on either occludin or 
ZO-1 organization in the colonic epithelium, where both placebo- and morphine-treated 
mice showed intact and continuous localization of occludin and ZO-1 (Figure 2.3F). This 
finding suggests the differential regulation of barrier functions in different compartments 
of the gastrointestinal epithelium. 
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Morphine treatment up-regulates TLR expression in epithelial cells of small intestine. 
 
        As we have discussed previously, there is a clear correlation between TLR 
activation and tight junction disruption in intestinal mucosa, consistent with instances 
recently described in the literature(Sheth et al. 2007; Shifflett et al. 2005). To determine 
whether TLR expression on gut epithelial cells is one mechanism by which morphine 
modulates barrier function, we implanted mice with placebo or morphine pellets for 24 
hours and isolated epithelial cells from the small intestines as described previously. Total 
RNA was isolated from these cells and processed for qPCR. For flow cytometery, the 
isolated cells were gated by cytokeratin as an epithelial marker(Quinlan et al. 2006) 
(Figure 2.5A).Results showed 24 hours of morphine treatment up-regulated both mRNA 
(Figure 2.5B) and protein levels (Figure 2.5C–F) of TLR2 and TLR4. In addition, the 
messenger RNA levels of TLR2 and TLR4 in colonic epithelial cells following morphine 
treatment was determined by gel-based PCR. The results showed that neither TLR2 nor 
TLR4 was significantly up-regulated by morphine in the colonic epithelium in contrast to 
the observation in the small intestinal epithelium (Figure 2.6). 
 
 
Morphine-induced bacterial translocation is attenuated in TLR2/TLR4 knockout mice 
       To further determine roles of TLR2 and TLR4 in morphine-induced bacterial 
translocation, we implanted C57BL/6 J WT (n = 9), TLR2 knockout (n = 9), TLR4 
knockout (n = 9), and TLR2/4double knockout (n = 9) mice with morphine pellets to 
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determine bacterial load in MLN and liver as described previously. Placebo-treated TLR 
2, 4 KO mice showed very low basal levels of bacterial load in MLN and liver. 
Morphine-treated WT mice still showed significant bacterial translocation to MLN and 
liver. In contrast, morphine-treated TLR2, 4 knockout mice showed lower bacterial 
translocation into MLN and liver than did WT mice (Figure 2.7) although TLRKO did 
not show any effects on morphine-induced constipation, suggesting that constipation is 
not the only dominant factor causing bacterial translocation following morphine 
treatment and other TLR-dependent mechanisms also contribute to the process of TJ 
disorganization and barrier dysfunction (Figure 2.8). These findings indicated that both 
TLR2 and TLR4 are involved in morphine modulation of intestinal barrier function. 
 
TLR2/TLR4 knockout protects tight junction organization from morphine-induced 
disruption 
       To further determine the role of TLRs in morphine's modulation of intestinal tight 
junction proteins, we isolated the small intestine from WT, TLR2 knockout, TLR4 
knockout, and TLR2/4 double knockout mice to assess the organization of tight junction 
proteins, as described previously. In TLR2KO and TLR2/4KO mice, the occludin and 
ZO-1 staining were continuous and intact following morphine treatment (Figure 2.9A and 
B). In TLR4KO mice, some degree of tight junction disruption was observed following 
morphine treatment; however, the disruption was not as dramatic as that observed with 
morphine treatment in WT mice, suggesting a dominant role of TLR2 in morphine 
modulation of intestinal tight junction organization, which was consistent with our in 
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vitro study: small intestinal cell IEC-6 and colonic epithelial cell CMT-93 were stained 
for tight junction proteins ZO-1(Figure 2.10A). LPS and LTA but not morphine induced 
ZO-1 internalization. And morphine enhanced LTA's effects on IEC-6 cells, further 
validating that TLR2 plays a more dominant role in TJ modulation in gut epithelial cells 
following morphine treatment. In contrast, neither LPS nor LTA showed any effect on TJ 
distribution in colonic CMT-93 cells, consistent with our in vivo data (Figure 2.10B). 
 
TLR signaling modulates intestinal tight junction organization in a MLCK-dependent 
manner 
       Since our data (Figure 2.4) show that TLR ligands have no effect on tight junction 
protein expression levels, the increased permeability of epithelial cells by TLR activation 
may involve post-translation mechanisms. Recent studies showed that myosin light chain 
kinase (MLCK) regulates the contraction of tight junctions by phosphorylating myosin 
light chains(Utech et al. 2005; Moriez et al. 2005; Marchiando, Graham, and Turner 
2010). Activation of MLCK induces phosphorylation of the myosin light chains, resulting 
in the contraction of cytoskeleton proteins such as F-actin and thus inducing the 
internalization of associated tight junction proteins such as occludin and ZO-1. To 
determine whether MLCK is responsible, we determined the barrier function of IEC-6 
cells by electrical cell impedance sensing (ECIS) arrays. The cells were grown to 
confluence in ECIS arrays, and the trans-epithelial resistance (TER) values were 
measured to test whether morphine would affect epithelial barrier integrity. The baseline 
TER of each experiment was normalized to 1.0 to enable comparison and statistical 
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analysis of TER changes over time following different treatments. IEC-6 cells were 
treated with MLCK inhibitor ML-7, and the TER values were measured in the presence 
of LTA (Figure 2.11A) and LPS (Figure 2.11B). Inhibition of MLCK restored the TER 
values to the control levels, indicating that the effects of TLR agonists on epithelial cells 
are dependent on MLCK. To further validate the role of MLCK in tight junction 
modulation, WT mice were injected with 2 mg of ML-7/kg body weight prior to 
morphine treatment as described previously. ML-7 inhibited morphine-induced bacterial 
translocation to MLN and liver (Figure 2.11C), and protected occludin and ZO-1 
organization from morphine-induced disruption (Figure 2.11D), although it did not block 
constipation caused by morphine treatment (Figure 2.8). 
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DISSCUSSION 
       In the current study, we show that morphine mediated signaling by µ-opioid 
receptors 1) induced bacterial dissemination into MLN and liver of WT mice; 2) 
compromised intestinal barrier function; and 3) disrupted tight junction organization in 
gut epithelial cells through a TLR- dependent mechanism. 
 
       Our studies show significant bacterial translocation to the mesenteric lymph node 
and liver of WT mice that are morphine treated (Figure 2.1A and Figure 2.2). Over the 
past two decades, a large amount of studies have been conducted to investigate the effects 
of morphine on bacterial translocation and intestinal permeability using various rodent 
models. Consistently these studies demonstrate that morphine alters intestinal transit and 
promote bacterial translocation in rodents(Runkel et al. 1993; Kueppers et al. 1993) 
although in one study morphine only in the presence of TNF was able to increase 
intestinal permeability. Bacterial translocation was not measured in these studies (Leslie 
et al. 1994). It is not clear why there is a discrepancy between this study and the majority 
of other studies but the differences in the results may be attributed to differences in the 
doses of morphine used, the route of administration or the sensitivity of the permeability 
experiments. However, most recent studies clearly establish that morphine treatment in 
doses that are clinically relevant results in bacterial translocation in both rats and mice. In 
addition, we rule out the possibility that the bacteria detected in liver and lymph node is 
not a consequence of opportunistic infections due to suppressed immune function by 
morphine by measuring ampicillin-resistant E. coli and FITC-conjugated dextran 
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translocation (Figure 2.1C and D), validating that the observed bacterial translocation is a 
consequence of disrupted intestinal barrier function following chronic morphine 
treatment. We further show that morphine's effects were abolished in the MOR knockout 
mice (Figure 2.1B), indicating that morphine's modulatory effect on intestinal barrier 
function were mediated by MOR. 
 
        We then demonstrated through morphological evaluation of the gut that morphine 
potentiated inflammation in small intestine. Histological analysis showed injured 
epithelium and increased inflammatory infiltrates in the villi of the small intestines in 
morphine-treated mice (Figure 2.3), which was usually associated with disrupted 
intestinal barrier function. Interestingly, we failed to observe any effect of morphine on 
colonic epithelium (Figure 2.3), suggesting a differential effects of morphine on small 
intestinal and colonic derived epithelium, despite the observation that MOR expression is 
similar in the colon and in the small intestine. These observations are consistent with the 
previous studies where it was demonstrated that tolerance to morphine is differentially 
regulated in the ileum versus the colon(Ross et al. 2008). Although, in this study, the 
cellular basis for the differential expression of morphine tolerance in the ileum versus the 
colon was not defined, it is conceivable that signaling downstream of MOR activation 
may contribute to the differential effect. 
        Our studies also demonstrated that the organization of tight junction proteins in 
small intestines were disrupted following morphine treatment (Figure 2.3A to D), 
suggesting paracellular translocation of bacteria from the gut lumen. Tight junction 
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proteins have been shown to seal the gap between gut epithelial cells and play an 
important role in preventing potential pathogen invasion. Interestingly, morphine did not 
affect tight junction proteins' expression levels in intestinal epithelial cells (Figure 2.4), 
implying that it is their distribution that is involved in modulating intestinal permeability. 
To understand the cellular mechanism underlying tight junction modulation by morphine, 
we used IEC-6 cells as an in vitro model and determined its tight junction distribution 
following morphine treatment. To our surprise, morphine alone showed no effect on tight 
junction of epithelial cells. However, we observed that TLR2 and TLR4 ligands disrupted 
the tight junction organization of monolayers formed by small intestinal epithelial cells 
(IEC-6). Morphine modulated TJ organization of IEC-6 cells only in the presence of 
TLR2 ligand, suggesting that morphine's effects were mediated by TLRs. On the other 
hand, neither morphine nor TLR ligands showed any effect on barrier function of colonic 
epithelial cells (Figure 2.10), implying differential regulation of TJ in the ileum and colon 
by TLRS. 
        Historically, many studies have investigated the role of TLRs in modulating tight 
junctions in various epithelial cells: invasive bacterial pathogens S. pneumoniae and H. 
influenzae were observed to translocate across the epithelium through TLR-dependent 
down-regulation of tight junction components(Clarke TB, Francella N, Huegel A 2011). 
LPS also has been reported to disrupt tight junction of cholangiocytes-the epithelial cells 
of the bile duct by a TLR4-dependent mechanism(Sheth et al. 2007). Our in vivo studies 
support the role of TLRs in tight junction modulation in gut epithelial cells. Protein levels 
of TLR2 and TLR4 were increased in small intestine following morphine treatment 
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(Figure 2.5). Bacterial translocation and tight junction disruption were significantly 
attenuated in TLR2KO, TLR4KO, and TLR2/4 double knockout mice following 
morphine treatment (Figure 2.7 and 2.9), demonstrating that both TLR2 and TLR4 
contribute to morphine-induced intestinal barrier disruption. Interestingly, TLR4 
signaling was not involved in morphine modulation of epithelial barrier function in IEC-6 
cells (Figure 2.11), which was contradictory to our in vivo study, where we show 
significant protection of tight junction from morphine-induced disruption in TLR4 
knockout. These results suggest that activation of TLR4 in other cell types and not on the 
epithelial cells may play a more dominant role in morphine modulation of epithelial 
barrier function. TLR4 has been shown to play an important role in cytokine production 
in gut associated lymphoid tissue (GALT), which plays crucial roles in maintaining intact 
intestinal barrier function and defense against potential pathogen invasion. We postulate 
that TLR4 activation in the GALT, but not in epithelial cells, is involved in gut barrier 
modulation. In support of this hypothesis, it has been demonstrated that abnormal pro-
inflammatory cytokine production induced by translocated bacteria causes disruption of 
tight junction proteins in gut epithelium. This feed-forward vicious cycle contributes to 
serious gut inflammatory disease and even sepsis. Therefore, it is conceivable that other 
factors activated by TLR4 may play a role in disrupting intestinal barrier function by 
modulating pro-inflammatory cytokines TNF-alpha and IL-6(Bruewer et al. 2003). 
          In addition, both in vitro and in vivo studies demonstrated that the distribution of 
tight junction was modulated by myosin light chain kinase (MLCK). MLCK inhibition 
completely blocked LTA- and LPS- induced barrier dysfunction in IEC-6 cells and 
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morphine-induced bacterial dissemination in mice (Figure 2.11), which confirmed that 
the impaired barrier function of epithelial cells following TLR activation is due to 
MLCK-induced redistribution of tight junction proteins rather than decreased tight 
junction protein expression levels. 
         In summary, our studies demonstrate that morphine treatment up-regulates TLR 
expression levels in small intestinal epithelial cells and sensitized small intestinal 
epithelial cells to TLR stimulation, which induced disruption of tight junctions between 
epithelial cells, increased gut permeability, and resulted in increased bacterial 
translocation and inflammation in the small intestine (Figure 2.12). In contrast, colonic 
epithelium did not show any response to morphine treatment, suggesting differential 
effects of morphine on small intestinal and colonic barrier function. Currently, opiates are 
among the most prescribed drugs for pain management. However, they induce multiple 
adverse gastrointestinal symptoms including dysfunction of the gut immune system, 
which may lead to a higher risk of gut bacterial infection as well as faster progression of 
infectious diseases such as sepsis. These adverse effects seriously affect patients' quality 
of life and limit the prolonged use of opiates for pain management. These studies 
contribute to the urgent need to understand the mechanism through which morphine 
modulates intestinal barrier function, enhancing our ability to develop novel strategies for 
treating or preventing gut bacterial infection in opiate-using or -abusing populations. 
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FIGURE 2.1 
 
FIGURE 2.1 Chronic morphine compromises barrier function of gut epithelium and 
promotes bacterial translocation. Wild type (A) and MORKO (B) mice were treated 
with 75 mg morphine pellets for 24 hours, MLN and liver homogenates were cultured on 
blood agar plate overnight. Bacterial colonies were quantified and described as colony 
forming units (CFU). ** p<0.01 *P<0.05 by Mann-Whitney test 
   55 
 
FIGURE 2.1 
 
FIGURE 2.1 Chronic morphine compromises barrier function of gut epithelium and 
promotes bacterial translocation. (C) WT mice were gavaged with ampicillin -resistant 
E. coli after morphine treatment, and the number of E. coli in MLN and liver were 
quantified using an LB agar plate containing ampicillin. (D) The permeability of gut 
epithelium increased after morphine treatment as determined by measuring the whole 
blood FITC-dextran concentration.– Median of CFU; (C)** p<0.01 *P<0.05 by Mann–
Whitney test. (D) **P<0.01 by Student's t-test. 
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FIGURE 2.1 
 
FIGURE 2.1 Chronic morphine compromises barrier function of gut epithelium and 
promotes bacterial translocation. (E) Wild type mice were treated with 75 mg 
morphine pellets for 24 hours, MLN and liver homogenates were cultured on blood agar 
plate overnight. Bacterial colonies were quantified and described as colony forming units 
(CFU).  
 
 
 
 
 
 
 
FIGURE 2.2 
E 
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FIGURE 2.2  Chronic morphine induces inflammation in small intestine. 
Representative hematoxylin and eosin (H&E)-stained sections from the small intestine 
and colon of placebo- and morphine- treated WT mice. White arrow indicates 
inflammatory cell infiltration. 
 
 
 
 
 
 
FIGURE 2.3 
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FIGURE 2.3 Chronic morphine disrupts tight junction organization between small 
intestinal epithelial cells. (A) Occludin organization in small intestine of WT mice. (C) 
ZO-1 organization in small intestine of WT mice. Quantification of co-localization of 
occludin (B) or ZO-1 (D) with F-actin are showed as relative intensity of yellow 
fluorescence normalized to blue fluorescence (DAPI)  The same parts of small intestines 
and colons were excised and fixed. Images were analyzed by confocal scanning 
microscope. (n = 5) Scale bar: white 50 µm; yellow 10 µm * P<0.05, **P<0.01 by 
Student's t-test. 
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FIGURE 2.3 
 
FIGURE 2.3 Chronic morphine disrupts tight junction organization between small 
intestinal epithelial cells. (E) Occludin and ZO-1 organization in small intestine of 
MORKO mice. (F) Occludin and ZO-1 organization of colon in WT mice. WT and 
MORKO mice were treated with 75 mg morphine pellet for 24 hours. The same parts of 
small intestines and colons were excised and fixed. Images were analyzed by confocal 
scanning microscope. 
 
 
 
 
 
 
FIGURE 2.4 
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FIGURE 2.4 Occludin and ZO-1 expression of total small intestinal epithelial cells. 
Small intestinal epithelial cells were isolated from placebo and morphine-treated mice 
and lysed with RIPA buffer. The sample was used for WB. Figure B is the quantification 
of 3-time experiments. 
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FIGURE 2.5 
 
 
FIGURE 2.5 Morphine treatment upregulates TLR expression in small intestinal 
epithelial cells.(A) Isolated cells were fixed using eBioscience Fixation and 
Permeabilization Kit and then incubated with anti-cytokeratin antibody or isotype 
control. Cytokeratin positive cells were gated in P2 according to isotype control. (B) 
Real-time PCR analysis of mRNA levels of TLR2 and TLR4 in epithelial cells of small 
intestine after 24 hour morphine treatment.  * P<0.05 by Student's t-test. 
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FIGURE  2.5 
 
FIGURE 2.5 Morphine treatment upregulates TLR expression in small intestinal 
epithelial cells. (C) and (E) Representative expression of TLR2 and TLR4 in epithelial 
cells of small intestine after 24 hour morphine treatment from 3-time experiments. (D) 
and (F) Frequencies of TLR2 and TLR4 positive cells within cytokeratin positive cells. * 
P<0.05 by Student's t-test. 
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FIGURE 2.6 
 
FIGURE 2.6 MOR expressions in small intestinal and colonic epithelial cells. Gel-
based PCR analysis of mRNA levels of MOR in epithelial cells of small intestinal and 
colonic epithelial cells. SI: Small intestine; C: Colon. 
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FIGURE 2.7 
 
Figure 2.7 Morphine-induced bacterial translocation is attenuated in TLR2/TLR4 
knockout mice. WT, TLR2 knockout, TLR4 knockout, and TLR2/4 double knockout 
mice were implanted with 75 mg morphine pellet for 24 hours; MLN(A), liver (B) were 
cultured on blood agar plates overnight. Bacterial colonies were quantified and described 
as CFU. – Mean of CFU *P<0.05, **P<0.01 by ANOVA one-way analysis, followed by 
Bonferroni post-test (n = 9). 
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FIGURE 2.8 
 
FIGURE 2.8 Morphine induces constipation in mice. Pictures of intestines from 
placebo- and morphine-treated WT, TLR2KO, TLR4KO, TLR2/4KO mice and mice 
treated with ML-7 or vehicle. 
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FIGURE 2.8 
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FIGURE 2.9 
 
FIGURE 2.9 TLR2/TLR4 double knockout protects tight junction organization 
from morphine-induced disruption. (A) Occludin organization in small intestine of WT 
and TLRKO mice. (B) ZO-1 organization in small intestine of WT and TLRKO mice. 
WT, TLR2 knockout, TLR4 knockout, and TLR2/4 double knockout mice were 
implanted with 75 mg morphine pellet for 24 hours. The similar parts of small intestines 
were excised and fixed. Images were analyzed by confocal scanning microscope. (n = 5) 
Scale bar: 10 µm. 
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FIGURE 2.10 
 
FIGURE 2.10 Morphine's effects on tight junction of IEC-6 and CMT-93 cells. IEC-
6 and CMT-93 Cells were fixed and incubated with anti-zo-1 antibody, followed by 
FITC-labeled secondary antibody. Magnification ×600. 
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FIGURE 2.10 
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FIGURE 2.11 
 
FIGURE 2.11 TLR signaling modulates intestinal tight junction organization in a 
MLCK-dependent manner.(A) Effects of LTA on TER of IEC-6 cells are blocked by 
MLCK inhibition. (B) Effects of LPS on TER of IEC-6 cells are blocked by MLCK 
inhibition. (C) Bacterial translocation to MLN and liver are blocked by MLCK inhibition. 
** p<0.01 *P<0.05 by Mann-Whitney test.  
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FIGURE 2.11 
 
FIGURE 2.11 TLR signaling modulates intestinal tight junction organization in a 
MLCK-dependent manner. (D) MLCK inhibition protects tight junction organization 
following morphine treatment. (n = 6) Scale bar: 10 µm. 
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FIGURE 2.12 
 
FIGURE  2.12  Model of morphine-induced disruption of gut epithelial barrier 
function. Morphine treatments up-regulate TLR expression levels in small intestinal 
epithelial cells. Activated TLR signaling induces tight junction disruption between 
epithelial cells and increases gut permeability, resulting in increased bacterial 
translocation. 
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CHAPTER 3 
OPIOID TREATMENT MODULATES IMMUNE 
RESPONSES OF GALT 
 
INTRODUCTION 
        Sepsis is a life threatening complication of infection. Infection-induced systemic 
inflammation contributes to multi-organ dysfunctions, resulting in high mortality(Angus 
and van der Poll 2013). International epidemiological studies show that the incidence of 
sepsis is increasing and half of the cases are occurring in the intensive care units (ICUs). 
Today, sepsis has become the leading cause of death in the ICUs with mortality rate as 
high as 60%, and accounts for approximately 40% of total ICU expenditures(Vincent et 
al. 2009). 
        Opioids are widely used in ICU patients for pain management and to optimize 
patient comfort and facilitate mechanical ventilation due to their potent analgesic 
activities and sedative properties(Devlin and Roberts 2009). However, the adverse effects 
associated with opioid therapy raise safety issues especially in ICU patients. The 
immunosuppressive effects of opioids are well documented (Sabita Roy et al. 2011). In 
clinical studies, higher circulating morphine levels were observed in patients with sepsis, 
severe sepsis, and septic shock compared with healthy controls(Glattard et al. 2010). 
Animal studies also showed that morphine treatment induced bacterial translocation from 
gut lumen into peritoneal organs including mesenteric lymph nodes (MLN), liver, and 
subsequently, the circulatory system(Hilburger et al. 1997; Meng et al. 2013). In addition, 
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morphine has been shown to accelerate the progression of LPS-induced sepsis by 
interfering with endotoxin tolerance(Banerjee et al. 2013). However, the clear 
mechanisms by which opioids modulate sepsis progression still remain largely elusive. In 
the present study, the cecal ligation and puncture procedure (CLP) was used to induce 
polymicrobial sepsis in C57BL/6J mice treated with opioids or placebo. The responses 
and the survival rate of mice were analyzed to investigate the effects of opioids on sepsis 
progression. Our results demonstrated that both morphine and methadone increased 
mortality of animals following CLP. And morphine treatment increased bacterial 
dissemination and pro-inflammatory cytokine interleukin-17A (IL-17A) and interleukin-6 
(IL-6) production during sepsis progression.  
        IL-17A is a member of the interleukin-17 (IL-17) family consisting of a subset of 
cytokines that participate in both acute and chronic inflammatory responses. In various 
infectious diseases, IL-17A is involved in neutrophil recruitment and host defense and 
implicated in excessive inflammation and overt tissue damage(Gu, Wu, and Li 2013). To 
date, the roles of IL-17A in the sepsis progression have not been well characterized. Our 
study show that overexpression of IL-17A following morphine treatment resulted in 
increased gut permeability, higher bacterial load in different organs, sustained 
inflammation, and subsequently higher mortality. More importantly, neutralization of IL-
17A protected morphine-treated animals from sepsis-induced mortality. 
        In addition, we also show that morphine modulation of IL-17A response was 
mediated by the gut microbiome. Morphine treatment induced enrichment of gram-
positive bacteria Staphylococcus and Enterococcus in the gut lumen. Subsequently, more 
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Staphylococcus and Enterococcus disseminated to various organs and were recognized by 
Toll like receptor 2 (TLR2). TLR2 is a member of the pattern recognition receptor (PRR) 
family, specially recognizing cell-wall components such as peptidoglycan, lipoteichoic 
acid and lipoprotein from gram-positive bacteria(Takeda, Kaisho, and Akira 2003). 
Activation of TLR2 led to overexpression of IL-17A, resulting in excessive 
inflammation, and consequently accelerated progression of sepsis and higher mortality 
compared with placebo-treated animals. These results are consistent with an interesting 
clinical observation that the most common gram-positive isolates from patients with 
sepsis are Staphylococcus aureus. Additionally, infection with Enterococcus species has 
been considered as one independent factor associated with greater risk of hospital 
death(Vincent et al. 2009). Therefore, our studies provide insights into the influence of 
opioids on sepsis progression; implying that the therapeutic window for the dose of 
opioids used in ICU patients is narrow and that IL-17A may be the potential therapeutic 
targets to treat sepsis caused by gram-positive infection, especially in ICU patients who 
are on a moderate to severe pain management regimen.  
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METHODS 
Experimental animals and cell lines 
        Male C57BL/6 and TLR2KO mice were purchased from Jackson Laboratories (Bar 
Harbor, Maine). All animals were maintained in pathogen-free facilities and all 
procedures were approved by the University of Minnesota Institutional Animal Care and 
Use Committee. Typically, 8–10 week old animals were used for our studies. IEC-6 cell 
lines was obtained from American Type Culture Collection and cultured as recommended 
by the supplier. IEC-6 cells are rodent small intestinal epithelial cell lines, which have 
been used for studying intestinal barrier and integrity in previous publications. 
 
Induction of sepsis using CLP model and opioid treatment  
        Polymicrobial sepsis was induced as previously described(Toscano, Ganea, and 
Gamero 2011). Mice were anesthetized with 3% isoflurane, a 1-cm midline incision was 
made on the anterior abdomen. The cecum was exposed and ligated and the distance from 
the distal end of cecum to ligation point was approximately 1 cm. A double puncture was 
made with 22-gauge needle to induce sepsis. The cecum was squeezed to allow cecum 
contents to be expressed through the punctures. The cecum was placed back in the 
abdominal cavity and the peritoneal wall and skin incision were closed. All animals 
received 1 ml of saline by subcutaneous injection immediately after the surgery. Sham-
operated animals (controls) underwent identical laparotomy but without cecum ligation or 
puncture. The survival rates of animals were observed every 12 h up to 7 days after 
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surgery. For morphine treatment, a small incision was made at the dorsal torso of the 
mice. The appropriate pellet was inserted into the small pocket created during incision 
and the wound was closed using stainless steel wound-clips. For methadone treatment, 
saline or 15mg/kg of methadone was given by intraperitoneal injection. For IL-17A 
neutralization, 100µg of LEAFTM anti-mouse IL-17A antibodies (BioLegend) were 
administered to mice by intraperitoneal injection every other day. 
 
Bacterial counts in blood, peritoneal lavage, MLN, liver and spleen  
        The bacterial counts were determined 6, 24, 72, and 168 hours after CLP surgery in 
the peritoneal lavage, MLN, liver, spleen and blood. Peritoneal lavage, blood, and 
homogenates of liver, MLN, and spleen were cultured on blood agar plate overnight. 
Bacterial colonies were quantified and described as colony forming units (CFU). 
 
Cytokine measurements 
        The cytokine levels were detected in peritoneal lavage, serum, and supernatant of 
MLN cells.  The following mouse ELISA kits were used:  IL-1β, IL-6, IL-23, IL-17A, 
(eBiosciences).  All experiments were performed according to the manufacturer’s 
protocol. 
 
Flow cytometry analysis 
       MLN was homogenized and single cell suspension was incubated with anti-CD3, 
anti-CD4, and anti-IL-17A antibodies following manufacturer’s intracellular staining 
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protocol (eBiosciences). 
 
Intestinal permeability 
         Animals were gavaged with 4kD FITC-dextran (500 mg/kg body weight in 
50mg/ml concentration) utilizing a 4-cm long, curved needle with a plastic ball at the tip. 
The images of animals were analyzed using Xenogen Spectrum system.  After sacrifice, 
blood and peritoneal lavage were collected and the intensity of FITC was determined 
with a fluorometer using an excitation wavelength of 488 nm, and detecting emission at 
520 nm. 
 
Dendritic cell isolation  
       Dendritic cells from blood of wide type or TLR2KO were purified by magnetic 
separation (Miltenyi Biotec) according to the manufacturer’s instruction. 
 
Measurement of trans-epithelial resistance  
        ECIS 1600R (Applied BioPhysics, Troy, NY) was used to measure trans-epithelial 
resistance (TER) of epithelial monolayers as described previously(Schlegel et al. 2010). 
Epithelial cells were seeded in the wells of the electrode array and grown to confluence 
as indicated below. Then medium was changed, and baseline TER was measured for 60 
min to equilibrate monolayers. Afterward, 400 ml of medium containing different 
concentrations of IL-17A was applied to each well. The baseline TER of each experiment 
was normalized to 1.0 to enable comparison and statistical analysis of TER changes over 
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time following different treatments. 
 
Transwell assays 
        Transwell assay was performed as described previously(Wójciak-Stothard et al. 
2001).IEC-6 cells were cultured in the top chamber of transwell system and 5mg/ml 4kD 
FITC-dextran was added to the top chamber after 24 hours of IL-17A (100ng/ml) 
stimulation. The medium in the lower chamber was taken after 6 hours. The amounts of 
FITC-dextran in the lower chambers were determined with a fluorometer using an 
excitation wavelength of 488 nm, and detecting emission at 520 nm. 
 
Immunofluorescence 
        IEC-6 cells in the chamber slides were fixed with 1% paraformaldehyde in PBS for 
10 min at room temperature. After washing in PBS and blocking of nonspecific binding 
sites with 5% bovine serum albumin (BSA), slides were incubated with polyclonal rabbit 
anti-ZO-1 (both used at 5 mg/ml, Invitrogen) in PBS with 5% bovine serum albumin 
(BSA) for 120 min at room temperature. After washing, slides were incubated with 
rhodamine phalloidin (Invitrogen) and DyLightTM 488-conjugated AffiniPure Donkey 
anti-rabbit IgG (0.075 mg/ml, Jackson Lab, WestGrove, PA) for 60 min. Slides were then 
washed and mounted under coverslips using ProLong Gold antifade reagent with DAPI 
(Invitrogen). Slides were imaged using a confocal microscope (Nikon). 
 
Gut microbiome analysis 
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       Fecal content was collected from gut region encompassing distal cecum and 
approximately one inch of the colon. The gut tissue was washed and stored separately. 
The fecal matter was lysed using glass beads in MagnaLyser tissue disruptor (Roche) and 
total DNA isolated using Power-soil/fecal DNA isolation kit (Mo-Bio) as per 
manufacturer’s specifications. All samples was quantified via the Qubit® Quant-iT 
dsDNA Broad-Range Kit (Invitrogen, Life Technologies, Grand Island, NY) to ensure 
that they met minimum concentration and mass of DNA and submitted to Second 
genome Inc. for microbiome analysis as follows: To enrich the sample for the bacterial 
16S V4 rDNA region, DNA was amplified utilizing fusion primers designed against the 
surrounding conserved regions which are tailed with sequences to incorporate Illumina 
(San Diego, CA) flow cell adapters and indexing barcodes. Each sample was PCR 
amplified with two differently bar coded V4 fusion primers and were advanced for 
pooling and sequencing. For each sample, amplified products were concentrated using a 
solid-phase reversible immobilization method for the purification of PCR products and 
quantified by electrophoresis using an Agilent 2100 Bioanalyzer®.The pooled 16S V4 
enriched, amplified, barcoded samples were loaded into the MiSeq® reagent cartridge, 
and then onto the instrument along with the flow cell. After cluster formation on the 
MiSeq instrument, the amplicons were sequenced for 250 cycles with custom primers 
designed for paired-end sequencing. Using QIIME and custom scripts, sequences were 
quality filtered and demultiplexed using exact matches to the supplied DNA barcodes. 
Resulting sequences were then searched against the Greengenes reference database of 
16S sequences, clustered at 97% by uclust (closed-reference OTU picking). The longest 
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sequence from each Operation Taxonomic Unit (OTU) thus formed was then used as the 
OTU representative sequence, and assigned taxonomic classification via mothur's 
bayesian classifier, trained against the Greengenes database clustered at 98%. 
 
Statistical analysis 
        The data (except for the survival curves and scatter plots) were reported as the 
means + SEM of values of triplicates. The means of different treatments were compared 
by student t test or ANOVA followed by Bonferroni’s t test (GraphPad Prism Software). 
Bacterial counts were reported as means of CFU and were analyzed by the Mann-
Whitney U test (GraphPad Prism Software). The survival rate was expressed as the 
percentage of live animals, and the Mantel-Cox log rank test was used to determine 
differences between survival curves (GraphPad Prism Software version 3). A p value of 
0.05 or less was considered significant. For gut microbiome analysis, the Adonis test was 
utilized for finding significant whole microbiome differences among discrete categorical 
or continuous variables. In this randomization/Monte Carlo permutation test, the samples 
were randomly reassigned to the various sample categories, and the mean normalized 
cross-category differences from each permutation were compared to the true cross-
category differences. The fraction of permutations with greater distinction among 
categories (larger cross-category differences) than that observed with the non-permuted 
data reported as the p-value for the Adonis test. 
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RESULTS 
Opioids increased mortality rates in a polymicrobial sepsis model induced by CLP. 
        To determine the effects of opioids on the outcome of polymicrobial sepsis, 
C57BL/6J wild type (WT) mice were subjected to polymicrobial sepsis using the CLP 
model and implanted with placebo or 25mg morphine pellet subcutaneously. There was a 
significant decrease in the weight of the animals from Day1 to day3 following CLP due 
to diarrhea. However from Day 4, no weight loss was observed and the animals showed 
signs of recovery (Figure 3.1A). In contrast, morphine’s anti-diarrhea effects attenuated 
weight loss in mice following CLP (Figure 3.1A). Interestingly, the survival rates of mice 
after CLP were not associated with the weight loss. As shown in Figure 3.2A, morphine-
treated mice showed significant reduction in survival rate following CLP. At 24h after 
CLP, 100% of placebo-treated mice were alive compared with only 66.67% in morphine-
treated mice. None of the morphine treated mice survived beyond 96 hours while 78.57% 
of placebo-treated mice survived for the whole period of the observation (p < 0.01 by 
Mantel-Cox log rank test). All the sham-operated mice treated with placebo pellet 
survived for the whole period of observation while 80% of sham-operated mice treated 
with morphine pellet survived. To investigate the influence of other prescription opioids 
on outcome of CLP-induced sepsis, we also injected methadone or saline to mice after 
the CLP procedure. Methadone showed the similar effects on survival rates of mice 
following CLP (Figure 3.2B). 66.67% of saline-treated mice were alive for the whole 
period of observation (7days) whereas no methadone-treated mice survived on the fifth 
day after CLP (p<0.05 by Mantel-Cox log rank test). All the sham-operated mice injected 
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with saline or methadone survived for 7 days after the procedure. Moreover, morphine 
and methadone-induced mortality following CLP was significantly reduced by the opioid 
receptor antagonist naltrexone (Figure 3.2C and D), indicating that opioid treatment 
influenced the outcome of polymicrobial sepsis in an opioid receptor-dependent manner. 
 
Morphine promoted bacterial dissemination and inhibited bacterial clearance during 
sepsis. 
        To understand the mechanism underlying the higher mortality in our sepsis model 
associated with opioid treatment, we determined the bacterial load in the peritoneal 
lavage, mesenteric lymph node (MLN), liver, spleen, and blood at different time points 
following CLP in the presence or absence of morphine treatment.   
       As shown in Figure 3.3, at 24 hours, morphine treatment alone induced bacterial 
translocation into the peritoneal cavity, MLN, liver, and spleen, implying that morphine 
itself could compromise gut epithelial barrier function. In the placebo-treated CLP 
animals, the amount of bacterial in peritoneal lavage, MLN, liver, spleen, and blood 
reached the highest levels at 24 hours, and decreased at 72 hours. 168 hours after CLP, 
almost all bacteria disseminated into peritoneal lavage, MLN, liver, spleen, and blood 
were cleared in the placebo-treated animals. In the morphine-treated mice that were 
subjected to CLP, a significant increase in the amount of bacteria in peritoneal lavage, 
MLN, liver, spleen, and blood was observed when compared to the placebo-treated mice 
at both 24 and 72 hours, indicating that morphine treatment promoted bacterial 
dissemination and inhibited bacterial clearance. Since none of the animals survived 
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beyond 168 hours in the morphine-treated group, data on bacterial load was not available 
for that time point for morphine-treated animals. 
 
Morphine treatment modulated microbiota in the gut lumen. 
        We next serotyped the bacterial species disseminated into the MLN, liver, and spleen 
following CLP to identify the bacterial species. In placebo-treated CLP animals, the most 
common bacterial species detected in MLN, Spleen, and liver were non-haemolytic 
Escherichia coli (Figure. 3.4A) which were common gram negative commensal bacteria 
resident in gut lumen, and only small amount of Enterococcus were detected in MLN and 
spleen. However all MLN, spleen, and liver isolates from morphine-treated animals with 
or without CLP procedure revealed a prevalence of the gram-positive families 
Staphylococcus and Enterococcus (Fig. 3.4A). 
       Interestingly, analysis of the gut microbiome showed that morphine treatment 
induced enrichments of mostly the Firmicutes phylum and specifically the gram positive 
bacterial species staphylococcus sciuri, staphylococcus cohnii, and staphylococcus 
aureus as well as enterococcus durans, enterococcus casseliflavus, enterococcus faecium, 
and enterococcus faecalis in the gut lumen (Fig. 3.4B and C), all of which belonged to 
the gram positive family of bacteria. Interestingly, these were also the same species that 
were observed to translocate to various organs following morphine treatment. Morphine-
induced alterations of gut microbiome was antagonized by the opioid receptor antagonist 
naltrexone, further validating that morphine treatment modulated gut microbiome and 
thereby influenced the outcome of polymicrobial sepsis in an opioid receptor-dependent 
manner. 
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Morphine up-regulated IL-17A production during sepsis 
        To determine the effects of morphine on the immune responses in the CLP-induced 
sepsis model, we collected serum, peritoneal lavage and MLN to measure IL-17A 
production at different time points. The results show that IL17A levels in peritoneal 
lavage and serum increased at 6 hours after CLP in both placebo and morphine-treated 
mice. In placebo-treated mice, IL-17A concentration reduced to baseline level at 24 hours 
while in the morphine group a sustained high level of  IL-17A was observed (Figure 3.5A 
and 3B). Previous studies showed that there were two sources of IL-17A in response to 
infections: the T helper 17 cells and type three innate lymphoid cells(Walker, Barlow, 
and McKenzie 2013). To determine which types of cells are producing IL-17A following 
CLP procedure, we used anti-CD3 and anti-CD4 antibodies to separate MLN cells into 
two populations: CD3+CD4+ T helper cells and CD3- non-T Cells. The flow cytometry 
analysis showed that placebo-treated animals did not show significant up-regulation of 
IL-17A at 24 hours alter CLP (Figure 3.4C and 3.4E). In contrast, a significant increase 
in IL-17A production was observed in the morphine treated animals. Further 
characterization revealed that the major source in MLN of IL-17A was from the 
CD3+CD4+ T helper cells which increased significantly (Figure 3.5C) but not CD3- non-
T Cells (Figure 3.5E).  
 
Neutralization of IL-17A improved survival rate and attenuated sustained 
inflammation in CLP mice treated with morphine 
        To investigate the role of IL-17A in sepsis progression following morphine 
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treatment, a neutralizing monoclonal antibody to IL-17A or isotype control IgG was 
administered to morphine-treated mice by intraperitoneal injection after the CLP 
procedure. As shown in Figure. 3.6A, when morphine-treated mice were administered 
with anti-IL-17A, the survival rate was significantly improved (65.6% survival) at 96 
hours after CLP, whereas none of isotype injected control mice survived. For the whole 
period of observation (7days), the survival rate of mice treated with anti-IL-17A was 
52.5% (Figure 3.6A). Additionally, mice treated with anti-IL-17A showed significantly 
reduced bacterial disseminations to peritoneal lavage, MLN, and liver at 24 hours 
following CLP compared with isotype-control-treated animals (Figure 3.6B-D), implying 
that neutralization of IL-17A following CLP improved gut barrier functions. It has been 
reported that serum levels of IL-6 is a good marker for severity during sepsis12. Thus, we 
determined the IL-6 levels in serum at different time points following CLP. ELISA 
results showed that in placebo-treated animals, serum IL-6 peaked to 1700pg/ml at 24 
hours after CLP and then reduced to baseline levels at 72 hours while morphine-treated 
mice showed sustained high levels of IL-6 in serum even at 72 hours following CLP 
(Figure 3.6E). Neutralization of IL-17A significantly decreased IL-6 serum level in the 
morphine-treated animals at 72 hour after CLP (Figure 3.6F), validating the pro-
inflammatory role of IL-17A during sepsis progression.  
 
High levels of IL-17A compromised gut epithelial barrier function and increased gut 
permeability. 
        To determine the gut permeability during sepsis progression, we gavaged the mice 
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with fluorescein isothiocyanate (FITC) labeled dextran and tracked the diffusion of 
dextran using Xenogen Spectrum imaging system. As shown in Figure 3.7A, morphine 
treatment resulted in an increase in FITC-dextran diffusion across the gut epithelium, 
indicating that morphine treatment increased gut permeability during sepsis. To further 
validate that gut permeability was increased by morphine treatment, we quantified FITC-
dextran in the peritoneal lavage and blood.  In morphine-treated animals, FITC intensities 
were significantly higher in both peritoneal lavage and blood compared with placebo-
treated animals (Figure 3.7B). In morphine treated animals that were injected with anti-
IL-17A antibodies, we observed a decrease in FITC-dextran diffusion across the gut 
epithelium into the peritoneal cavity and blood (Figure 3.7C and D), demonstrating that 
neutralization of IL-17A restored gut barrier function in morphine-treated CLP animals. 
To investigate the effects of morphine on the morphology of the intestinal epithelium in 
CLP animals, small intestine and colon were excised and fixed in a formalin solution for 
hematoxylin and eosin (H&E) staining. Histological analysis indicated severe epithelial 
injury in small intestinal villi of morphine-treated mice after CLP compared with the 
appearance of continuous epithelial cells lining gut mucosal surfaces in placebo-treated 
mice (Fig 3.7E). Interestingly, the morphology of the colonic epithelium were not 
affected by morphine treatment (Figure 3.8), suggesting differential sensitivities of 
colonic and small intestinal epithelial cells to inflammatory stimulation. Neutralization of 
IL-17A also protected the epithelial structure of small intestines in morphine-treated mice 
following CLP (Figure 3.7F).To determine the direct effects of IL-17A on small intestinal 
epithelial cells, we determined the barrier function of IEC- 6 cells, which are rat small 
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intestine epithelial cells, by electrical cell impedance sensing (ECIS) arrays. The cells 
were grown to confluence in ECIS arrays, and the trans-epithelial resistance (TER) 
values were measured to test whether IL-17A would affect epithelial barrier integrity. 
The baseline TER of each experiment was normalized to 1.0 to enable comparison and 
statistical analysis of TER changes over time following different treatments. IEC-6 cells 
were treated with different concentrations of IL-17A (Figure 3.7G). TER values were 
significantly reduced following IL-17A treatment and the duration of the effects of IL-
17A persisted for a longer time as its concentration increased. We further determined the 
barrier function of IEC-6 cells using a trans-well system. Tans-well assay showed that 
both apical and basolateral stimulation with 100ng/ml of IL-17A increased permeability 
of IEC-6 monolayer (Figure 3.7H). Next, we investigated the organization of tight 
junction proteins between the epithelial cells which plays an important role in modulation 
of the epithelial barrier function. Staining of tight junction protein zona occludens 1 (ZO-
1) in IEC-6 cells also indicated the disruptive effects of IL-17A on IEC-6 monolayer 
(Figure 3.7I). As shown in Figure 3.6I, ZO-1 (green color) localized with F-actin (red 
color) on the apical side of the membrane in vehicle-treated cells, and its organization 
was seen to be disrupted following 6 hours of IL-17A stimulation. 
 
Gram Positive Bacteria Stimulated MLN to produce IL-17A in a TLR2-dependent 
manner. 
        To investigate the mechanism by which morphine modulated IL-17A production in 
CLP animals, we cultured the immune cells from MLN in vitro and stimulated the cells 
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with either a gram negative bacteria species (E. coli) or the gram positive species that 
translocated into the MLN following morphine treatment, which were mixture of 
Enterococcus and Staphylococcus. The results showed that E. coli was able to induce 
higher levels of IL-6 production when compared with mixture of Enterococcus and 
Staphylococcus however high levels of IL-17A were only observed when MLN cells 
were stimulated by Enterococcus and Staphylococcus (Figure 3.9A and B). Meanwhile 
MLN cell were treated with morphine and IL-17A concentrations in the supernatant were 
measured by ELISA at different time points following gram positive bacteria stimulation. 
Interestingly, morphine treatment alone did not show any direct effects on IL-17A 
production by MLN cells (Figure 3.9C). TLR2 has been shown to play an important role 
in recognizing cell-wall components from gram-positive bacteria and initiating the 
immune responses to pathogen stimulation. To understand the role of TLR2 in IL-17A 
production by MLN, we measured IL-17A production in serum, peritoneal lavage, and 
MLN in TLR2KO mice following CLP procedure. No IL-17A induction was observed in 
placebo or morphine-treated CLP TLR2KO animals, strongly implying the role of TLR2 
in IL-17A responses during CLP-induced sepsis (Figure 3.9D to F). 
        To understand the different roles of specific immune cells in IL-17A response, we 
separate the adherent cell and non-adherent cell as described previously(Weinberger et al. 
1980) and stimulated the cells with gram positive bacterial mixture separately. No IL-
17A induction were observed (Figure 3.9G), suggesting that antigen presenting cells were 
required for an IL-17A response. Since dendritic cells have been shown to initiate IL-17 
responses(Akdis et al. 2012), we isolated non-adherent cells from MLNs of WT or 
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TLR2-knockout (TLR2KO) mice and co-cultured them with dendritic cells purified from 
the blood of WT or TLR2KO mice. The flow-cytometic analysis indicated that 
approximately 80% of non-adherent cells in MLN were CD3+ T cells (Figure 3.10). In 
response to bacterial stimulation, WT and TLR2KO T cells which were co-cultured with 
WT dendritic cells were able to produce high levels of IL-17A. Conversely, when 
TLR2KO T cells and WT T cells were co-cultured with TLR2KO dendritic cells, no 
significant IL-17A induction was observed (Figure 3.9H), indicating that TLR2 expressed 
on dendritic cells was an essential requirement for IL-17A production. Interestingly, 
deficiency of TLR2s in T cells attenuated the IL-17A production significantly (Figure 
3.9H), implying that TLR2s on T cells were also involved in maximal IL-17A response.  
IL-1β and IL-23 promoted IL-17A production by MLN Cells 
        Previous studies have shown that IL-17A production was mediated by IL-6, TGF-β, 
IL-1β or IL-23 in different cell types(Kim et al. 2013; Reynolds et al. 2010; Taylor et al. 
2014; Rubino, Geddes, and Girardin 2012). To determine the role of each cytokine in 
IL17A production by MLN, we measured the concentrations of IL-6, TGF-β, IL-1β, or 
IL-23 in MLN adherent cell supernatant at different time points following bacterial 
stimulation. We observed significant up-regulation of IL-6, IL-1β, and IL-23 at 24 hours 
which trended towards reduction after 48 hours. In contrast, no TGF-β up-regulation was 
observed until 48 hours after bacterial stimulation (Figure 3.11 A to D). We next 
determined the role of these cytokines in IL-17A production by using cytokine 
neutralization antibodies (5µg/ml) (Figure 3.11 E to I). As shown in Fig. 3.11E and F, 
neutralization of IL-6 or TGF-β showed no effects on IL-17A production. In contrast, 
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neutralizing IL-1β and IL-23 inhibited IL-17A production and IL-1β showed a more 
dominant role in IL-17A modulation (Figure 3.11 G to I). Additionally, IL-1β alone was 
sufficient to induce IL-17A production and the mixture of IL-1β with IL-23 showed 
synergistic effects on IL-17A induction in MLN cells (Figure 3.11J), further validating 
the roles of IL-1β and IL-23 in IL-17A responses.  
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DISCUSSION  
        Sepsis is a more complex and variable syndrome than normal infections, in which 
pro-inflammatory mechanism contributes to pathogen clearance as well as tissue damage 
and multiple organ failure. To date, the Surviving Sepsis Campaign has issued the third 
iteration of clinical guidelines for the management of severe sepsis and septic shock 
while the mortality rate of sepsis still remains high(Angus and van der Poll 2013; 
Investigators 2014; Vincent et al. 2009). Previous studies have identified many factors 
independently associated with greater risks of death in septic cases including comorbid 
cancer, heart failure, immunosuppression, cirrhosis to name a few(Vincent et al. 2009). 
Several studies indicate that morphine treatment results in spontaneous sepsis in 
mice(Hilburger et al. 1997) and that opioid antagonist naltrexone block acute endotoxic 
shock(Greeneltch et al. 2004b), however  the underlying mechanism that contributes to 
sepsis progression and outcome following opioid treatment has not been completely 
elucidated. In the present study, two commonly prescribed opioids morphine and 
methadone were administered to mice in the context of polymicrobial sepsis. Both 
opioids significantly increased mortality rates of septic mice, suggesting that the 
therapeutic window of opioids for pain management might be narrower in ICU patients 
who are septic. A large amount of clinical and laboratory studies have provided strong 
evidences that multiple mechanisms are involved in opioid-induced immunosuppression 
(Ninković and Roy 2013; Wang et al. 2005; Sabita Roy et al. 2011; Breslow et al. 2010; 
Hilburger et al. 1997; Börner and Kraus 2013), which are consistent with our 
observations. We also demonstrate that morphine treatment inhibited neutrophil 
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recruitment into the peritoneal cavity  in the early stages of sepsis (Figure 3.12) and also 
induced splenic atrophy (Figure 3.13), implying that the defensive functions of immune 
cells and organs against infections during sepsis were compromised by morphine 
treatment. The compromised immune function led to delayed bacterial clearance 
following CLP in morphine-treated animals, resulting in sustained high bacterial load in 
different organs and circulatory systems. In addition to higher bacterial load, we also 
found that gram-positive bacterial families Staphylococcus and Enterococcus showed 
higher potential for translocating across the gut epithelium following morphine treatment. 
Even morphine treatment alone induced the translocation of these two bacteria families, 
suggesting that opioid treatment might be an independent risk factor for gram-positive 
infections with gut origin. The imbalance of gut microbiota and increased prevalence of 
staphylococcus and Enterococcus in the gut lumen following morphine treatment might 
be responsible for bacterial translocation. Interaction between gut microbiota and 
intestinal epithelial surface play important roles in the prevention of pathogenic bacterial 
outgrowth and maintaining gastrointestinal homeostasis(Hill and Artis 2010). Changes in 
composition or density of the microbiota may lead to higher susceptibility to a variety of 
pathogens and abnormal mucosal immune responses(Kamada et al. 2013). In our sepsis 
model, the overgrowth of staphylococcus and enterococcus in the gut lumen following 
morphine treatment resulted in gram positive bacterial dissemination and excessive 
systemic inflammation. The overexpression of pro-inflammatory cytokine IL-17A 
following specific gram positive bacteria stimulation induced gut epithelial damage and 
promoted further bacterial translocation. This vicious cycle contributes to accelerated 
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progression of infection and high mortality following the CLP procedure. The present 
study is an example of how alterations in gut microbiota determine the immune responses 
of the host and predict the outcome of infectious diseases, which support microbiota 
manipulation strategies to control or treat infectious diseases. 
         Up-regulation of IL-17A associated with morphine treatment in our sepsis model 
prompted us to investigate the roles of IL-17A in sepsis progression. IL-17A is a pro-
inflammatory cytokine involved in the initiation and maintenance of several autoimmune 
disorders such as encephalomyelitis, and inflammatory bowel disease(Akdis et al. 2012; 
Towne et al. 2012). And one of the most important mechanisms involved in excess 
inflammation associated with high levels of IL-17A is that IL-17A is able to modulate 
tight junction protein organization in endothelial cells and thereby promoting blood-brain 
barrier disruption and central nervous system inflammation(Huppert et al. 2010; Kebir et 
al. 2007). Increased IL-17 production has been shown to be associated with compromised 
gastrointestinal integrity in pigtail macaques(Klatt et al. 2010). Our stuides similarly 
show that overexpression of IL-17A during sepsis induced epithelial barrier dysfunction 
by disrupting the organization of tight junction proteins in gut epithelial cells. The role of 
IL-17A in these defects are supported by the observation that neutralization of IL-17A 
controlled the inflammation and protected morphine-treated animals from death 
following the CLP procedure, which was consistent with Flierl’s observation that IL-17A 
promoted inflammation and showed adverse functions in adult mice with severe 
sepsis(Flierl et al. 2008). Studies in contrary however show that IL-17 receptor signaling 
was required to control sepsis(Deshmukh et al. 2014; Freitas et al. 2009). This 
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inconsistency may be explained by the differences in experimental approaches used: 
Deshmukh and Freitas used IL17R knockout mice or neutralized IL-17A in neonatal 
mice. Lack of IL-17 signaling in infant mice might result in compromised development 
of neutrophils and other immune cells, which may have contributed to the increased host 
susceptibility to infections.  
       The major sources of IL-17A in our study are CD4+ helper T (TH) cells. To date, 
scientists have identified two different population of TH17 cells: one being the inducible 
TH17 (iTH17) cells that arise from naive CD4+ T cells in response to antigen and 
cytokine stimulation and the other the natural TH17(nTH17) cells that acquire the 
capacity to produce IL-17 during development in the thymus(Kim et al. 2013). The 
nTH17 cells are poised to rapidly produce IL-17 upon stimulation without further 
differentiation in the peripheral tissues(Kim et al. 2011) and show great recruitment to the 
gut Peyer’s patches and lamina propria(Marks et al. 2009). The presence of nTH17 cells 
may explain the quick IL-17A responses to bacterial stimulation in our study. Another 
unexpected observation we have made is that IL-17A production by MLN following 
gram positive bacterial stimulation was independent of IL-6 and TGF-β, the key 
cytokines driving TH17 differentiation in previous publications(Chang and Dong 2011; 
Gu, Wu, and Li 2013; Taylor et al. 2014). In our sepsis model, dendritic cells expressing 
TLR2 were required for a robust  IL-17A response, which was mediated by IL-1β and IL-
23. Recently many researchers suggest that the CD4+ T cells will differentiate into more 
regulated classical TH17 cells in the presence of TGF-β. In contrast, the TGF-β 
independent pathway will generate more pathogenic alternative TH17 cells, which are 
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responsible for the excessive inflammation in many autoimmune disorders(Akdis et al. 
2012). Our results support this theory. We show that IL-17A induction is not dependent 
on IL-6 or TGF-β, instead requires  IL-1β and IL-23 to produce pro-inflammatory and 
pathogenic IL-17A. The induction of IL-17A contributes to gut epithelial damage, 
compromised barrier function,  leading to continuous bacterial dissemination and 
sustained high levels of inflammation. In addition, we also observed that TLR2 on T cells 
were involved in the  IL-17A response, which was consistent with Joseph M’s study: 
TLR2 agonists activated TLR2 signaling in CD4+ T cells and led to more robust 
proliferation and TH17 cytokine production, resulting in more severe pathology in 
autoimmune disease like EAE(Reynolds et al. 2010). The present study further lends 
support to the pro-inflammatory role of IL-17A  in the progression of sepsis. Today, fast 
development of antibiotic resistance in various pathogens is a growing threat to the world 
and researchers have paid more attentions to developing novel anti-cytokine strategies for 
controlling infectious diseases rather than rely on antibiotics alone. However, no current 
large-scale trials of anti-cytokine molecules in the treatment of sepsis has achieved 
satisfying efficacy(Angus and van der Poll 2013). Therefore, our study may provide 
novel therapeutic targets to develop anti-cytokine strategies to control specific gram 
positive infections especially in the context of opioid pain management. 
      To summarize, we report that during CLP-induced sepsis, morphine treatment 
induced enrichment of gram positive bacteria Staphylococcus and Enterococcus in the 
gut lumen and promote gram positive bacterial dissemination. Disseminated gram 
positive bacteria induced IL-17A overexpression in a TLR2-dependent manner. Excess 
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IL-17A increased gut permeability and contributed to higher mortality rate associated 
with opioid treatment, implying that opioid administration might contribute to higher risk 
of death for ICU patients and neutralization of IL-17A might be a novel strategy to 
control excess inflammation and to improve survival during sepsis.  
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FIGURES 
 
FIGURE 3.1 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3.1 Weight loss induced by sepsis was attenuated by morphine treatment. 
(A) Weight curves of sham-operated or CLP mice treated with placebo or 25mg 
morphine pellet.(B) Weight curves of sham-operated or CLP mice injected with saline or 
15mg/kg methadone. 
 
Da
y0
Da
y1
Da
y2
Da
y3
Da
y4
Da
y5
Da
y6
Da
y7
18
19
20
21
22
23
24
25
26
27
28
29
30
Saline
Methadone
Saline+CLP
Methadone+CLP
W
ei
gh
t/g
Da
y0
Da
y1
Da
y2
Da
y3
Da
y4
Da
y5
Da
y6
Da
y7
18
19
20
21
22
23
24
25
26
27
28
Placebo
Morphine
Placebo+CLP
Morphine+CLP
W
ei
g
h
t/
g
A 
B 
   99 
 
FIGURE 3.2 
 
 
FIGURE 3.2 Opioids increased mortality rates of polymicrobial sepsis induced by 
CLP. (A) Kaplan–Meier plots of sham-operated or CLP mice treated with placebo or 
25mg morphine pellet. ** p<0.01 compared with placebo-treated mice subjected to CLP 
(Mantel-Cox log rank test) (B) Kaplan–Meier plots of sham-operated or CLP mice 
injected with saline or 15mg/kg methadone. Numbers of mice used for each condition are 
shown in the frame. * p< 0.05 compared with saline-treated mice subjected to CLP 
(Mantel-Cox log rank test)  
C 
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FIGURE 3.2 
 
 
 
 
 
 
FIGURE 3.2 Opioids increased mortality rates of polymicrobial sepsis induced by 
CLP. (C) Kaplan–Meier plots of morphine-treated CLP mice treated with placebo or 
30mg naltrexone pellet. ** p<0.01 compared with placebo-treated mice (Mantel-Cox log 
rank test) (D) Kaplan–Meier plots of methadone-treated CLP mice treated with placebo 
or 30mg naltrexone pellet. * p<0.05 compared with placebo-treated mice (Mantel-Cox 
log rank test) Numbers of mice used for each condition are shown in the frame. 
C 
D 
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FIGURE 3.3 
 
FIGURE 3.3 Morphine Inhibited Bacterial Clearance and Promoted Bacterial 
Dissemination during Sepsis. (A) Peritoneal lavage was collected at different points and 
cultured on blood agar plate overnight. Bacterial colonies were quantified and described 
as CFU. (B) Bacterial colonies of MLN homogenates.  *P<0.05 compared with placebo-
treated animals ** p<0.01 compared with placebo-treated animals (Mann-Whitney U test) 
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FIGURE 3.3 
 
FIGURE 3.3 Morphine Inhibited Bacterial Clearance and Promoted Bacterial 
Dissemination during Sepsis. (C) Bacterial colonies of liver homogenates. (D) Bacterial 
colonies of spleen homogenates. *P<0.05 compared with placebo-treated animals ** 
p<0.01 compared with placebo-treated animals (Mann-Whitney U test) 
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FIGURE 3.3 
 
FIGURE 3.3 Morphine Inhibited Bacterial Clearance and Promoted Bacterial 
Dissemination during Sepsis. Wild type mice were treated with 25mg morphine 
pellets following CLP procedure. (E) Bacterial colonies of whole blood.*P<0.05 
compared with placebo-treated animals (Mann-Whitney U test) 
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FIGURE 3.4 
 
 
FIGURE 3.4 Morphine treatment modulated microbiome in gut lumen. (A) 
Serotyping of the disseminated bacteria in MLN, spleen, and liver from morphine and 
placebo-treated animals (Veterinary Diagnostic Laboratory, University of Minnesota). 
G+: Gram positive bacteria    G- : Gram negative bacteria 
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FIGURE 3.4 
 
FIGURE 3.4 Morphine treatment modulated microbiome in gut lumen. (B)-(C) 
Bacterial species identified in fecal contents from placebo or 25mg morphine pellet-
treated mice. 
B 
C 
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FIGURE 3.5 
 
FIGURE 3.5 Morphine modulated pro-inflammatory cytokine IL-17A production 
during sepsis. (A) IL-17A concentrations in peritoneal lavage at different time points 
following CLP. *p<0.05 (Student t test) (B) IL-17A concentrations in serum at different 
time points following CLP. *p<0.05 (Student t test) (C) IL-17A expression in MLN cells 
which were CD3+CD4+. (D) Frequencies of IL-17A positive cells in CD3+CD4+ cells. 
*p<0.05，**p<0.01 (ANOVA followed by Bonferroni’s t test) (E) IL-17A expression in 
MLN cells which were CD3- (F) Frequencies of IL-17A positive cells in CD3- cells 
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FIGURE 3.6 
 
FIGURE 3.6 Neutralization of IL-17A improved survival rate and attenuated 
sustained inflammation in CLP mice treated with morphine. (A) Kaplan–Meier plots 
of morphine-treated CLP mice injected with isotype control or anti-IL17A antibody  
p<0.01 compared with anti-IL17A-treated mice subjected to CLP (Mantel-Cox log rank 
test) (B) Bacterial colonies of peritoneal lavage (C) Bacterial colonies of MLN (D) 
Bacterial colonies of liver *p<0.05 (Mann-Whitney U test) 
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 FIGURE 3.6 
 
FIGURE 3.6 Neutralization of IL-17A improved survival rate and attenuated 
sustained inflammation in CLP mice treated with morphine. (E) IL-6 concentrations 
in serum at different time points following CLP. *p<0.05 **p<0.01 (Student t test) (F) 
IL-6 concentrations in serum in morphine-treated CLP mice injected with isotype control 
or anti-IL-17A antibody.  **p<0.01 (Student t test) 
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FIGURE 3.7 
 
FIGURE 3.7 High levels of IL-17A compromised gut epithelial barrier function and 
increased gut permeability. (A) Morphine increased FITC-dextran diffusion across the 
gut epithelium.  FITC-dextran diffusion across the gut epithelium in morphine-treated 
CLP animals. The right panel was quantification of FITC intensity.  (B) Quantification of 
FITC intensity in peritoneal lavage and whole blood (C) Anti-IL-17A injection reduced 
FITC-dextran diffusion across the gut epithelium in morphine-treated CLP animals. The 
right panel was quantification of FITC intensity.  *p<0.05 **P<0.01(Student t test)   
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FIGURE 3.7 
 
FIGURE 3.7 High levels of IL-17A compromised gut epithelial barrier function and 
increased gut permeability. (D) FITC intensity in peritoneal lavage and whole blood 
*p<0.05 (Student t test)  (E)  H&E sections of  small intestines from sham-operated or 
CLP animals treated with morphine or placebo. White arrow indicates epithelial 
disruption. 
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FIGURE 3.7 
 
FIGURE 3.7 High levels of IL-17A compromised gut epithelial barrier function and 
increased gut permeability. (F) H&E sections of small intestines form morphine-treated 
CLP animals injected with isotype control and anti-IL-17A. White arrow indicates 
epithelial disruption (G) TER was decreased by IL-17A in IEC-6 cell monolayer (H) The 
permeability of IEC-6 cell monolayer was increased in transwell system **p<0.01 
(ANOVA followed by Bonferroni’s t test) (I) ZO-1 organization in IEC-6 cell monolayer 
treated by vehicle or 100ng/ml IL-17A. Blue:DAPI  Red:F-actin  Green:ZO-1 White 
arrow indicates ZO-1 disruption 
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FIGURE 3.8 
 
FIGURE 3.8 Colonic epithelium was not affected by high levels of IL-17A. H&E 
sections of colons from sham-operated or CLP animals treated with morphine or placebo.
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FIGURE 3.9 
 
FIGURE 3.9 Gram Positive Bacteria Stimulated MLN to produce IL-17A in a 
TLR2-dependent manner. IL-6 (A) and IL-17A (B) concentrations of MLN cell 
supernatant stimulated by gram-positive or gram-negative bacteria. *p<0.05 (ANOVA 
followed by Bonferroni’s t test) (C) IL-17A concentrations of MLN supernatant treated 
with morphine or gram-positive bacteria ***p<0.001 (ANOVA followed by Bonferroni’s 
t test) (D) IL-17A expression in MLN cells from TLR2KO mice. The right panel is the 
frequencies of IL-17A positive cells in MLN from TLR2KO mice. 
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FIGURE 3.9 
 
 
FIGURE 3.9 Gram Positive Bacteria Stimulated MLN to produce IL-17A in a 
TLR2-dependent manner. (E) IL-17A concentrations in serum of TLR2KO mice. PC: 
placebo+CLP MC: morphine+CLP (F) IL-17A concentrations in peritoneal lavage of 
TLR2KO mice. PC: placebo+CLP MC: morphine+CLP (G) IL-17A concentrations in 
supernatant of adherent and non-adherent cells from MLN following gram-positive 
bacterial stimulation. (H) IL-17A concentrations in supernatant of non-adherent cells 
from MLN of WT or TLR2KO mice co-cultured with dendritic cells from blood of WT 
of TLR2KO mice ***p<0.001 (Two-way ANOVA followed by Bonferroni’s t test) 
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FIGURE 3.10 
 
 FIGURE 3.10 MLN cells were fixed and incubated with anti-CD3 antibodies and 
separated as two populations: CD3+ Cells and CD3- Cells. After separation, more than 
80% of non-adherent cells were CD3+ T cells.  
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FIGURE 3.11 
 
Figure 3.11 IL-1β and IL-23 promoted IL-17A production by MLN Cells (A)-(D) IL-
6 , TGF-β ,  IL-1β, and IL-23 concentrations of MLN adherent cell supernatant following 
G+ bacterial stimulation ***p<0.001 **p<0.01 (Two-way ANOVA followed by 
Bonferroni’s t test). 
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FIGURE 3.11 
 
Figure 3.11 IL-1β and IL-23 promoted IL-17A production by MLN Cells. (E)-(H) 
IL-17A concentrations of MLN supernatant following G+ bacterial stimulation in the 
presence of  isotype control, anti-IL-6, anti-TGF-β,anti-IL-1β or anti-IL-23p19 antibodies. 
***p<0.001 (ANOVA followed by Bonferroni’s t test). ***p<0.001 (ANOVA followed 
by Bonferroni’s t test) 
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FIGURE 3.11 
 
FIGURE 3.11 IL-1β and IL-23 promoted IL-17A production by MLN Cells. (I)  IL-
17A concentrations of MLN supernatant following G+ bacterial stimulation in the 
presence of isotype control, or anti-IL-1β and anti-IL-23p19 antibodies. ***p<0.001 
(ANOVA followed by Bonferroni’s t test) (j) IL-17A concentrations of MLN cell 
supernatant following IL-1β or IL-23 stimulation. ***p<0.001 (ANOVA followed by 
Bonferroni’s t test) 
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FIGURE 3.12 
 
FIGURE 3.12 Morphine inhibited neutrophil recruitment at early stage of 
sepsis.The numbers of neutrophils in peritoneal lavage at different time points were 
determined by anti-neutrophil antibodies (Abcam) **p<0.01 (Student t test) 
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FIGURE 3.13 
 
FIGURE 3.13 Morphine induced splenic atrophy. The weight of spleen were 
normalized to the whole body weight of mice .* p<0.05  **p<0.01 (Mann-Whitney U test 
test) 
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FIGURE 3.14 
 
Figure 3.14 Model of opioid modulation of sepsis progression. (a) Morphine treatment 
induces enrichments of gram-positive bacteria Staphylococcus and Enterococcus in the 
gut lumen and promotes gram-positive bacterial dissemination. (b) Disseminated gram-
positive bacteria induced IL-17A overexpression in a TLR2-dependdent manner. (c) 
Excess IL-17A disrupted tight junction organization and increased gut permeability, 
which contributed to sustained inflammation and higher mortality rate associated with 
opioid treatment. 
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CONCLUSION 
        Over centuries, opioid analgesics are considered the "gold standard" for pain relief. 
However, the adverse GI effects associated with opioid treatment especially their 
suppressive effects on gut immunity have become a growing concern for both physicians 
and patients. In our studies, we investigated the mechanisms underlying impaired gut 
immune function following opioid treatment, which provide insight on our understanding 
of the complicated mechanisms by which opioid treatment influence intestinal 
homeostasis and leading to alternate therapeutic strategies to control or prevent severe 
infectious diseases like AIDS and sepsis in the opioid using or abusing population. 
           Firstly, we observed that opioid treatment alone could induce bacterial 
translocation from the gut lumen through a paracellular pathway. The following study 
validated that the increased gut permeability following morphine treatment results from 
disrupted organization of tight junction proteins between the epithelial cells. However, 
morphine alone didn’t show any direct effects on intestinal epithelial cells in our in vitro 
studies. The results from TLRKO mice explained this inconsistency. Morphine-induced 
bacterial translation and tight junction disorganization were attenuated in TLR2KO, 
TLR4KO, and TLR2/4KO mice and both TLR2 and TLR4 expression levels were 
increased following morphine treatment, suggesting that morphine’s effects were 
mediated by TLR signaling. Finally, we showed that morphine by up-regulating TLR2 
and TLR4 sensitizes gut epithelial cells to TLR ligands in the gut lumen. The over-
activation of TLRs in intestines activated MLCK and subsequent induction and 
delocalization of F-actins, myosin, and other tight junction proteins, resulting in impaired 
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barrier function. 
               In addition to modulating TLRs in gut epithelial cells, we also showed that 
opioid treatment could modulate the immune responses during infection in a cecal 
ligation puncture (CLP) model, which could induce polymicrobial sepsis in mice. 
Following CLP procedure, we showed that opioid treatment could induce sustained 
bacterial dissemination and high levels of IL-17A responses via alteration of microbiota 
resident in the gut lumen. The overexpression of IL-17A led to impaired intestinal barrier 
function and prolonged inflammation, which may contribute to higher mortality of sepsis 
associated with opioid treatment. Neutralization of IL-17A improved survival rates and 
protected intestinal barrier function in the morphine-treated CLP animals, implying that 
IL-17A is a potential therapeutic target to treat sepsis in opioid use or abuse population.  
       Our discoveries have provided novel insights into the mechanisms by which opioids 
compromise gut immune system and increase host susceptibility to gut infections. 
However, limitations might attenuate its clinical relevance. The first limitation of our 
study is that we primarily used subcutaneous morphine pellets in our animal model. 
Today, the most common prescription opioids used for pain management are 
hydromorphone, oxycodone, and hydrocodone. Oxycodone and hydrocodone are 
especially popular since they can be taken orally. The gut epithelia of patients who are 
taking oxycodone or hydrocodone are exposed to high concentrations of opioids, which 
may exert distinct effects on the gut epithelial cells. Therefore, it will be worthwhile to 
investigate the specific effects of various prescription opioids and their route of 
administration on gut immunity. Second limitation is that we injected IL-17A 
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neutralization antibodies prior to CLP procedure, which reduced morphine-induced 
higher mortality rates and protected gut epithelial barrier function in our CLP model. 
Based on this observation, we believe that IL-17A will be a potential therapeutic target to 
control inflammation during sepsis progression. However, it is impossible for physicians 
to consider anti-cytokine treatment before clear diagnosis of sepsis. It will be important to 
determine whether delayed injection of anti-IL-17A could still protect mice from 
morphine-induced excessive inflammation in our sepsis model. Therefore, treatment of 
IL-17A neutralization antibodies at different time points after CLP procedure will 
provide a better clue whether IL-17A neutralization will benefit the septic patients and 
improve the prognosis of sepsis or septic shock. The third limitation is that we only show 
morphine treatment altered gut microbiota and thereby exacerbated the outcome of sepsis 
in mice model. The gut microbiota in humans is very different from those in mice. 
Therefore, to further validate the effects of opioids on human gut microbiota, it will be 
interesting to establish humanized mice model in a future study. By transplanting human 
immune cells into immunocompromised mice and gavaging these mice with human feces, 
we can mimic the interactions between human gut microbiota and human gut immune 
system in a humanized mice model and investigate the effects of opioids on human gut 
immune system. 
         In summary, the present study demonstrates that opioids treatment compromises gut 
epithelial barrier function by modulating TLR signaling and modulates immune 
responses of gut immune system by altering gut microbiota. It is important to note that 
the mechanisms by which opioids modulate gut immune system and thereby influence the 
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outcome of infectious diseases are very complicated. In order to provide a translational 
perspective to this study future studies are still needed to elucidate the mechanisms 
underlying increased host susceptibility to gut infections associated with opioid treatment. 
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